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ABSTRACT OF THE DISSERTATION 
 
Factors Promoting Human Papillomavirus Mediated Cervical Carcinogenesis 
by 
Yan Chen Wongworawat 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, June 2016 
Dr. Penelope J. Duerksen-Hughes, Chairperson 
 
High-risk human papillomavirus (HPV) is the causative agent of cervical cancer. 
Integration of the HPV genome into the host genome is a key event in cervical 
carcinogenesis, with oxidative stress (OS) likely playing a major role in promoting DNA 
damage, and subsequently, integration. In our current study, we demonstrated a chain of 
events leading from the induction of OS, to DNA damage, and then to viral integration. 
Induction of OS by either virus-mediated factors, such as expression of E6*, a splice 
variant of the E6 oncogene, or by exogenous factors led to DNA damage in normal oral 
keratinocytes and in cervical keratinocytes containing episomal HPV16. We found that 
OS increased the integration rate for both foreign DNA and HPV, while antioxidants 
reduced the integration frequency. We also demonstrated a significant variability in ROS 
levels in patient-derived cervical specimens, which may reflect differences in 
susceptibility to cervical cancer between women.
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CHAPTER ONE 
INTRODUCTION 
 
Viruses are the causative agents of approximately 10%–15% of all cancers 
worldwide. Viruses that have been linked to carcinogenesis include several DNA viruses: 
Kaposi’s sarcoma herpesvirus (KSHV), Merkel cell polyomavirus (MCV), Epstein-Barr 
virus (EBV), Human papillomavirus (HPV), hepatitis B virus (HBV) and the simian virus 
40 (SV40), as well as at least two RNA viruses: human T-lymphotropic virus-1 (HTLV-
1) and the hepatitis C virus (HCV). These viruses and their associated cancers are shown 
in Table 1. 
The mechanism of virus transmission varies depending on the type of virus, the 
type of infection, its targets and the associated life cycle. Sexual transmission has been 
attributed to HBV (Fairley & Read, 2012), HCV (Tohme & Holmberg, 2010) and HPV 
(Burchell, Winer, de Sanjose, & Franco, 2006). HBV and HCV infections can be also 
acquired from contaminated blood transfusions (Buddeberg, Schimmer, & Spahn, 2008; 
Wilkins, Malcolm, Raina, & Schade, 2010) or can be transmitted through needle sharing 
between intravenous drug users (Hughes, 2000; Wilkins et al., 2010). Perinatal 
transmission of HBV (Kazim, Wakil, Khan, Hasnain, & Sarin, 2002) and HCV (Lam, 
Gotsch, & Langan, 2010) has been observed from mother to child during pregnancy or 
labor, and EBV infections can be transmitted through saliva from one individual to 
another (Cozad, 1996). SV40 has the potential to be introduced into humans by the 
poliovirus vaccine (Shah, 2007). 
Progression to cancer as a result of infection with an oncogenic virus is usually a 
rare event. For example, the overall prevalence of high-risk HPV infection is 23% (Datta 
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et al., 2008). Most of these infections clear up without any intervention within a few 
months after acquisition, and about 90% clear within two years. Only 0.3%–1.2% of 
these initial infections will eventually progress to invasive cervical cancer, according to 
2013 World Health Organization (WHO) data (Shulzhenko, Lyng, Sanson, & Morgun, 
2014). Another example relates to the hepatitis B virus (HBV). The highest rate of 
infection was found in Sub-Saharan Africa and East Asia, where the prevalence of 
chronic hepatitis in the adult population is between 5%–10% according to 2014 WHO 
data ("WHO 2014 data: Hepatitis B,"). More than 90% of those infected people will 
recover and be completely cleared of the virus within six months, while less than 5% of 
infected people will develop chronic hepatitis. Twenty percent of chronic hepatitis B 
cases will progress to hepatic cirrhosis, and of these, only 5% will progress to 
hepatocellular carcinoma (HCC). In the case of another agent causing HCC, HCV, 
approximately 2%–3% (130–170 million) of the worldwide population has been infected 
with HCV (Negro & Alberti, 2011). According to 2014 data from the WHO, chronic 
HCV infection will develop in 55%–85% of infected persons, with the risk of hepatic 
cirrhosis being approximately 15%–30% within 20 years ("WHO 2014 data: hepatitis 
C,"). The transformation rate of cirrhosis to HCC is approximately 1%–3% per year 
(Rosen, 2011; Wilkins et al., 2010). According to WHO serological testing data, EBV, 
another oncogenic virus, is present in approximately 95% of adults worldwide, including 
those residing in the United States. However, only in very rare cases do these infections 
progress to Burkitt’s lymphoma or nasopharyngeal carcinoma. Similarly, the prevalence 
of HTLV-I infection in some endemic areas is 15% ("Recommendations for counseling 
persons infected with human T-lymphotrophic virus, types I and II. Centers for Disease 
 3 
Control and Prevention and U.S. Public Health Service Working Group," 1993), while 
adult T-cell leukemia (ATL) only develops in an estimated 2%–4% of these infected 
persons in endemic regions, and only where early childhood infection is common (Kondo 
et al., 1985; Murphy et al., 1989). Overall, these data indicate that infection with 
oncogenic viruses does not mean the obligatory development of cancer, although infected 
individuals can be considered an at-risk population for cancer development. 
Epidemiological studies demonstrate that risk factors for cancer include virus load, 
persistence of infection and duration of infection (C. J. Chen et al., 2006; Dalstein et al., 
2003). 
Although these viruses belong to different groups, display different etiologies, 
carry out a variety of life cycles, target different organs and utilize variable mechanisms 
to induce cancer, some common features of cancer development can be noted. Overall, 
these common features are related to virus-mediated and exogenously-derived factors that 
create favorable conditions for cancer promotion and progression.  
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Table 1. Oncogenic viruses and associated cancers 
HTLV-1, human T-lymphotropic virus-1; KSHV, Kaposi’s sarcoma herpesvirus; SV40, 
simian virus 40.  
 
Virus Genome Associated Cancers 
HTLV-
1  
Positive-strand, single-
stranded RNA retrovirus 
Adult T-cell leukemia (ATL) (Poiesz et al., 1980). 
ATL is a malignancy of CD4+ T-lymphocytes, which 
exhibits severe immunodeficiency and resistance to 
intensive chemotherapies (Yasunaga & Matsuoka, 
2007). 
HCV 
Positive-strand, single-
stranded RNA flavivirus 
Some hepatocellular carcinoma (HCC) and possibly 
some lymphomas (Choo et al., 1989; Marcucci & 
Mele, 2011). The risk of HCC is 11.5- to 17-fold in 
HCV-infected patients (Donato, Boffetta, & Puoti, 
1998; Donato et al., 2002). 
KSHV 
Double-stranded DNA 
herpesvirus 
Kaposi’s sarcoma, primary effusion lymphoma 
(Chang et al., 1994).  
Kaposi’s sarcoma is the most frequent cause of 
malignancy among AIDS patients. 
MCV 
Double-stranded DNA 
polyomavirus 
Merkel cell carcinoma (MCC) (Feng, Shuda, Chang, 
& Moore, 2008). MCC is a rare, but aggressive 
human skin cancer, and it typically affects the elderly, 
as well as immunosuppressed individuals. 
EBV 
Double-stranded DNA 
herpesvirus 
Most Burkitt’s lymphoma and nasopharyngeal 
carcinoma (Epstein, Achong, & Barr, 1964).  
HBV 
Partially double-stranded  
DNA hepadnavirus with 
retroviral features 
Chronic infection with HBV has been linked to the 
development of HCC for over 30 years (Blumberg, 
Alter, & Visnich, 1965; Di Bisceglie, 2009).  
HPVs 
A group of circular,  
double-stranded DNA  
viruses (Flores & Lambert, 
1997). 
High-risk human papillomaviruses (HPV) 16 and 
HPV 18 (some other α-HPV types are also 
carcinogenic) are associated with cervical cancer, 
penile cancers and some other anogenital and head 
and neck cancers (Boshart et al., 1984; Durst, 
Gissmann, Ikenberg, & zur Hausen, 1983). 
SV40 
Polyomavirus of the rhesus 
macaque (Shah, 2007) 
SV40 sequences are detected in 60% of human 
mesothelioma, a rare tumor related to exposure to 
asbestos (Carbone et al., 1994). It is also detected in 
brain tumors (Bergsagel, Finegold, Butel, Kupsky, & 
Garcea, 1992; H. Huang et al., 1999; Martini et al., 
1996), osteosarcoma (Martini et al., 2002) and  
non-Hodgkin lymphoma (NHL) (Shivapurkar et al., 
2002; Vilchez et al., 2002). 
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Mechanisms of Viral Carcinogenesis 
Cellular transformation is a multi-step process that results in the transformation of 
healthy cells into cancer cells. It requires a progression of changes at the cellular, genetic 
and epigenetic levels that ultimately lead to the cellular changes necessary for 
uncontrolled cell division and formation of a malignant mass. Hanahan and Weinberg, in 
their landmark review “Hallmarks of Cancer”, listed six essential alterations that must 
occur in a cell’s physiology to cause malignancy, including self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (Hanahan & Weinberg, 2000, 2011). More recently, two 
emerging hallmarks have been added to the list: deregulating cellular energetics and 
avoiding immune destruction (Hanahan & Weinberg, 2011). Cellular transformation 
induced by oncogenic viruses also adheres to Weinberg’s hallmarks; in particular, 
limitless replicative potential, evasion of apoptosis and genome instability (Hanahan & 
Weinberg, 2000). Viruses, when functioning as carcinogenic agents, utilize a variety of 
carcinogenic mechanisms to transform human cells. One such mechanism is direct 
transformation, where the virus expresses viral oncogenes that can directly transform 
infected cells. Several viruses, including HPV, EBV, KSHV, SV40, HCV and HTLV, 
encode oncoproteins that employ several mechanisms to inactivate two of the major 
regulators of genome stability, cell viability and cell cycle; namely, the p53 and 
retinoblastoma proteins (pRB) (Levine, 2009). 
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Direct Transformation through Expression of Viral Genes 
The tumor suppressor p53 is the product of the TP53 gene; it induces cell cycle 
arrest or apoptosis in response to cellular damage or insult, guards against genomic 
instability and plays a critical role in DNA repair (Collot-Teixeira, Bass, Denis, & 
Ranger-Rogez, 2004). Inactivation of p53 or depletion of its function in infected cells 
results in an accumulation of genomic mutations and DNA breaks, accumulating genomic 
instability, a loss of growth suppression and apoptosis, leading to promotion of cellular 
transformation (Collot-Teixeira et al., 2004; Weitzman, Lilley, & Chaurushiya, 2010). 
Perhaps the best-studied example of viral inactivation of p53 is provided by the E6 
protein from high-risk (HR) HPV. The HR HPV E6 protein induces ubiquitin-mediated 
degradation of p53, resulting in disabling of the normal cellular response to many insults, 
including the DNA damage response (Scheffner, Werness, Huibregtse, Levine, & 
Howley, 1990). Another example of a virus with the ability to inactivate p53 is KSHV. The 
large multifunctional protein latency-associated nuclear antigen 1 (LANA1) expressed by 
KSHV interacts efficiently with p53, represses its transcriptional activity and inhibits 
p53-induced cell death (Friborg, Kong, Hottiger, & Nabel, 1999). Furthermore, the SV40 
large T antigen (Tag) is well-known for its ability to bind and inactivate p53 (Carbone et 
al., 1997). In addition, it also plays a crucial role in cell-cycle derangement of human 
mesothelial cells (Levresse et al., 1997), followed by transformation of the cells (Butel & 
Lednicky, 1999). In the case of HCV, the NS5A viral oncoprotein is involved in 
apoptosis inhibition, signal transduction, transcription, transformation and the production 
of reactive oxygen species (ROS). In particular, NS5A has been shown to bind directly 
to p53 and to repress transcription of the tumor suppressor p21WAF1 in a p53-
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dependent manner (Lan et al., 2002; Majumder, Ghosh, Steele, Ray, & Ray, 2001; Tsai & 
Chung, 2010). 
In addition to p53, the tumor suppressor pRB is also a frequent target for 
oncogenic viruses. pRB regulates apoptosis during development, and its loss results in 
deregulation of growth and apoptosis (Hickman, Moroni, & Helin, 2002). In normal cells, 
pRB is hypophosphorylated in early G1, and becomes increasingly phosphorylated by 
cyclin D/CDK4/6 complexes as the cell moves towards S phase in response to a signal to 
divide. This results in the release of the E2F protein, which then activates the 
transcription of genes required for the S-phase transition (Hamid, Brown, & Gaston, 
2009). E7, another HPV oncogene, mimics this process by binding to pRB and releasing 
the E2F protein (Dyson, Howley, Munger, & Harlow, 1989), thereby driving quiescent, 
infected cells back into a proliferative state in order to enable viral genome replication 
(Munger et al., 1989). In addition, the HR HPV E7 protein binds directly to E2F-1, 
leading to the activation of E2F-1-dependent transcription, and the affinity of E7 for E2F-
1 appears to correlate with the oncogenic potential of the HPV (Hwang, Lee, Kim, Seo, 
& Choe, 2002). Therefore, HR HPV E6 works together with E7 to induce cellular 
genomic instability and mitotic defects, known contributors to carcinogenesis (Duensing 
et al., 2000). Another example of pRb inactivation is provided by the large T antigen 
(Tag) expressed by SV40. One domain of Tag, the LxCxE motif, binds to pRB and 
inactivates the protein (Ali & DeCaprio, 2001; De Luca et al., 1997). Despite the fact that 
adenoviruses do not cause cancer in humans, they can disrupt the pRB-E2F interactions 
via the activity of E1A, thus driving expression of viral transcription and inducing cell 
cycle progression (Seifried et al., 2008). 
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In addition to these two major targets, pRB and p53, several other molecules 
serve as common targets for oncogenic viruses. Telomerase, which is usually found in 
embryonic cells and is absent in somatic cells, is one such target. In normal cells, the 
telomeric regions shorten with each round of division (Campisi, Kim, Lim, & Rubio, 
2001); inappropriate expression of telomerase can lead to immortalization. HR HPV E6 
can activate the expression of the catalytic subunit of telomerase, telomerase reverse 
transcriptase (hTERT) (Klingelhutz, Foster, & McDougall, 1996; Veldman, Horikawa, 
Barrett, & Schlegel, 2001), in order to maintain telomeres through telomerase activation 
(Oh, Kyo, & Laimins, 2001; Veldman, Liu, Yuan, & Schlegel, 2003), and thereby 
contributing to immortalization. Another virus, EBV, encodes a principal oncoprotein, 
latent membrane protein 1 (LMP1), which is also able to activate hTERT (Terrin et al., 
2008). HTLV-I expresses Tax protein, which is believed to be critical in the 
transformation of infected cells to adult T-cell leukemia (ATL). Tax is a 40-kDa trans-
regulatory protein encoded by the tax gene located in ORF IV of the pX region (Jeang, 
Giam, Majone, & Aboud, 2004). Tax can repress the expression of hTERT by competition 
with c-Myc through a canonical c-Myc binding site within the hTERT promoter (Gabet et 
al., 2003). In addition to this function, it can also reprogram G1 to S progression through 
direct protein-protein binding, transcriptional induction/repression and post-translational 
modification (Jeang et al., 2004). Another target of oncogenic viruses is the tumor 
suppressor RASSF1A. The inactivation of this gene is correlated with the 
hypermethylation of its CpG-island promoter region, and the silencing of RASSF1A 
induces telomerase activity (Foddis et al., 2002). Tag of SV40 not only inactivates p53, 
but also inactivates the RASSF1A gene (Toyooka et al., 2002; Toyooka et al., 2001). 
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Several other signaling pathways involved in carcinogenesis are directly regulated 
by multifunctional viral oncoproteins. For example, the SV40 Tag can activate growth 
factor receptors, such as Met (Cacciotti et al., 2001), Notch-1 (Bocchetta, Miele, Pass, & 
Carbone, 2003) and IGF- 1R (Pass et al., 1996), leading to the activation of the ERK-
kinase and AP-1 pathways that promote cell division and contribute to SV40-induced 
carcinogenesis (Carbone, Pass, Miele, & Bocchetta, 2003). In addition, NS5A, the HCV 
protein that depletes p53, can also interact with Bax and prevent apoptosis in a p53-
independent manner (Chung, Sheu, & Yen, 2003). KSHV can express an interferon 
regulatory factor (IRF)-like signal-transduction protein, ORF K9, and this protein inhibits 
interferon-induced signaling pathways. This inhibition allows KSHV to overcome 
interferon-mediated antiviral activity and, thus, can contribute to host cell transformation 
(Moore & Chang, 1998). The LMP1 oncoprotein expressed by EBV (Mosialos et al., 
1995), as well as Tax expressed by HTLV-I (Yasunaga & Matsuoka, 2007), both target 
the Nuclear Factor-κB (NF-κB) pathway. The NF-κB pathway plays a critical role in 
regulating the immune response to infection. NF-κB is a crucial mediator of inflammation-
induced tumor growth and progression, as well as an important modulator of tumor 
surveillance and rejection (Karin & Greten, 2005). 
Indirect Transformational Activities 
In addition to these direct mechanisms underlying virus-induced carcinogenesis, 
virus-induced chronic infection and inflammation can also function as indirect 
transforming agents (zur Hausen, 2001). In fact, Colotta et al. in a 2009 paper in 
Carcinogenesis refer to inflammation as the seventh hallmark of cancer (Colotta, 
Allavena, Sica, Garlanda, & Mantovani, 2009). Evidence of the carcinogenic potential of 
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inflammation is provided by chronic inflammatory bowel diseases, such as chronic 
ulcerative colitis and Crohn’s disease, which can lead to colon cancer, even in the 
absence of other factors (Coussens & Werb, 2002). Another well-known example is the 
chronic infection and inflammation induced by Helicobacter pylori, which results in 
stomach cancer worldwide (Ernst & Gold, 2000). Inflammation can also be caused by 
infection with viruses, thereby providing another linkage between infection and 
carcinogenesis. For example, chronic HBV or HCV infection can lead to hepatocellular 
carcinoma (HCC) through a process that induces cell death, regeneration, cirrhosis and, 
finally, cancer (Mason, Liu, Aldrich, Litwin, & Yeh, 2010; Seeger & Mason, 2000; Tsai 
& Chung, 2010). In many cases, the inflammation induced by chronic infection creates a 
microenvironment that favors expression of viral oncogenes. For example, in HBV-
induced HCC, HBV is clonally integrated into host DNA, and the integrated HBV 
sequences encode HBV X (HBx) and/or truncated envelope pre-S2/S proteins in a large 
portion of the HCC. These oncoproteins are thought to participate in directly promoting 
transformation of hepatocytes to HCC (Tsai & Chung, 2010). Another example of the 
way in which virus infections can indirectly contribute to carcinogenesis is provided by 
cutaneous papillomavirus infections, which contribute indirectly to skin carcinogenesis 
by blocking apoptosis in cells exposed to ultraviolet light and, thus, permitting the 
survival of UV-damaged cells (Jackson & Storey, 2000). 
DNA Damage and Viruses 
p53 has been termed “the guardian of genome integrity.” Its depletion or 
inactivation by virus proteins, as well as the inflammation produced as a result of chronic 
infection, both lead to an accumulation of point mutations, genomic instability and DNA 
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damage. DNA damage starts with a chemical modification to a base of DNA that induces 
a break in either one or both strands of the DNA (Hoeijmakers, 2009). In uninfected cells, 
DNA repair systems can recognize DNA damaged bases as abnormal structures and 
repair the damage prior to replication. The cell can call on several systems to repair DNA 
damage caused by both endogenous and exogenous factors, and these DNA repair 
pathways recognize both single-strand breaks (SSB) and double-strand breaks (DSB). 
SSB DNA repair mechanisms include direct repair, nucleotide excision repair, mismatch 
repair and base excision repair. The DSB repair mechanisms include homologous 
recombination and nonhomologous end joining (Basu, Yap, Molife, & de Bono, 2012). If 
the DNA damage cannot be completely repaired, this damage can lead to a deregulated 
cell cycle, genomic instability (Weitzman et al., 2010) and mutations associated with the 
development of cancer (Marnett, 2000; Valko, Rhodes, Moncol, Izakovic, & Mazur, 
2006b). However, activation of DNA damage response and cell cycle regulation by virus 
proteins benefit virus production by providing an S-phase-like replication environment, 
preventing apoptosis and promoting episome maintenance (Weitzman et al., 2010). 
DNA Damage and Virus Infection 
During viral infections, the host must maintain genome integrity through the 
activation of its surveillance network for detecting and repairing DNA damage. Many 
viruses can employ direct and/or indirect mechanisms to activate DNA damage signaling 
pathways (Weitzman et al., 2010), and this DNA damage signaling can be activated 
either by virus infection itself or the expression of viral proteins. One example of DNA 
damage signaling activated by virus infection is seen in the case of EBV infections, 
where infection induces the cellular DNA damage response and activates the ataxia 
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telangiectasia-mutated (ATM) signal transduction pathway (Kudoh et al., 2005). ATM is 
the primary signal kinase activated after sensor proteins detect DNA damage. 
Autophosphorylation of ATM can activate downstream substrates, such as checkpoint 
kinase Chk2 and the DNA damage response protein, 53BP1. Inhibition of ATM and 
Chk2 significantly increases the transformation efficiency of EBV-infected primary B-
cells (Nikitin et al., 2010). Another example is seen in the case of SV40 infection, where 
infection results in activation of ATM and endogenous ATM substrates (Shi, Dodson, 
Shaikh, Rundell, & Tibbetts, 2005). SV40 viral proteins can also induce the DNA 
damage response, as expression of the SV40 Tag protein activates the DNA damage 
response via binding to the mitotic spindle checkpoint kinase, Bub 1 (Hein et al., 2009). 
Activation of the DNA damage response is in the best interest of the virus, as it promotes 
SV40 viral DNA replication (Shi et al., 2005). In the case of HPV, expression of viral 
proteins from the HPV episome leads to ATM kinase activation, which, in turn, activates 
Chk2. Caspase activation due to Chk2 activity is necessary for productive viral genome 
amplification (Moody, Fradet-Turcotte, Archambault, & Laimins, 2007; Moody & 
Laimins, 2009). In any case, if the DNA damage repair system activated by the virus is 
not sufficiently efficient or if additional DNA damage induced by exogenous sources 
accumulates in the host genome, one side effect of this increased DNA damage in 
infected cells can be the integration of viral genomes to the host genome. In the case of 
HPV and HBV, viral genome integration is a major trigger point for the development of 
cancer. The role and importance of viral genome integration in cancer development 
will be discussed below. 
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Factors that Cause DNA Damage and Contribute to Carcinogenesis 
Factors that induce DNA damage in infected cells can be divided into 
endogenous, i.e., virus mediated, and exogenous factors. 
Inflammation and DNA Damage Induced by Virus Itself 
Inflammation is a primary immune response to infection by pathogens (Williams, 
Filippova, Soto, & Duerksen-Hughes, 2011). That process involves activation and 
directed migration of leukocytes from the venous system to the sites of infection; tissue 
mast cells also play a significant role (Coussens & Werb, 2002). A family of chemokines 
attract leukocytes, whose persistence at an inflammatory site is important in the 
development of chronic disease (Coussens & Werb, 2002). 
Inflammation is referred to as a cancer “promoter”, because it induces cell 
proliferation, recruits inflammatory cells, increases cellular levels of ROS, thereby leading 
to oxidative DNA damage, and reduces DNA repair (Coussens & Werb, 2002). The 
deregulation of cell death and/or repair programs results in DNA replication and 
proliferation in chronically-inflamed tissue (Coussens & Werb, 2002). Inflammation also 
causes resistance to apoptosis, secretion of pro-angiogenic and immunosuppressive 
factors, invasion and metastasis (Peebles et al., 2007) that are attributes of carcinogenesis. 
For example, the most common type of liver cancer results from chronic liver 
inflammation induced by either HBV or HCV (Brechot et al., 2010; Di Bisceglie, 1997). 
The enhanced DNA replication and DNA damage created during chronic inflammation 
increase the number of free DNA ends in host genomic DNA and promote HBV 
integration (Bonilla Guerrero & Roberts, 2005). In case of HCV, its core protein interacts 
with the signal transducer and activator of transcription 3 (STAT3) protein (T. Yoshida et 
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al., 2002), a transcription factor involved in mediating cytokine signaling (Bromberg & 
Darnell, 2000). This interaction results in enhanced proliferation and up-regulation of Bcl-
XL and cyclin-D (T. Yoshida et al., 2002). In this way, chronic liver inflammation 
induced by HCV may alter the local cytokine profile and the balance between apoptosis 
and proliferation. 
Inflammation and DNA Damage Induced by Co-Infections 
Co-infections with certain sexually transmitted diseases (STD) cause cervical 
inflammation and increase the risk of cervical cancer in HPV-infected women (Castle & 
Giuliano, 2003; Castle et al., 2001; Williams et al., 2011). Furthermore, high levels of 
inflammatory mediators, such as cyclooxygenase (COX)-2, an enzyme responsible for 
prostaglandin formation, are observed in cervical cancer (G. E. Kim et al., 2004; Kulkarni 
et al., 2001). However, this inflammation is not thought to be primarily due to the HPV 
infection itself, but rather due to other factors, such as co-infections. One reason for the 
lack of HPV-induced inflammation is that HPV infects basal keratinocytes that are distant 
from immune centers and have short lifespans. In addition, the virus does not destroy the 
cells it infects, thereby avoiding the triggering of inflammation (Stanley, 2006). Co-
infections that do trigger inflammation can be of either viral or bacterial origin. For 
example, studies have determined that co-infection with either Chlamydia trachomatis or 
HSV increase the risk of developing cervical cancer (Finan, Musharrafieh, & Almawi, 
2006), as does infection with other STDs, such as Neisseria gonorrhoeae (Hawes & 
Kiviat, 2002). The inflammation induced by these co-infections can induce the generation 
of ROS, which can contribute to carcinogenesis by damaging DNA, as described below. 
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Oxidative Stressors, Viruses and Cancer 
ROS and reactive nitrogen species (RNS) are charged free radicals that are 
primarily generated in mitochondria as by-products of aerobic respiration, cytochrome 
P450 activity and peroxisome function (Jezek & Hlavata, 2005). Under normal 
conditions, the pro- and anti-oxidant systems maintain ROS homeostasis. A lack of 
proper balance between these two sets of systems results in changes to cellular levels of 
ROS and can lead to oxidative stress (OS). In general, the sources of OS can be divided 
into two broad categories: exogenous and endogenous. Endogenous OS, as discussed 
above, is primarily derived from natural processes, such as cellular signaling, metabolic 
processes and inflammation (Altieri, Grillo, Maceroni, & Chichiarelli, 2008; Cadet, Douki, 
& Ravanat, 2010; De Bont & van Larebeke, 2004; Sedelnikova et al., 2010). Exogenous 
and environmental sources include ionizing radiation, such as X-, γ- and cosmic rays, α-
particles from radon decay, oxidizing chemicals and UVA solar radiation. For example, 
ionizing radiation generates radicals, including superoxide, hydrogen peroxide and 
hydroxyl radicals (Riley, 1994), most of which are generated during the radiolysis of 
water. Of these, the hydroxyl radical is the most damaging species and produces mostly 
single-strand breaks (Wallace, 1998). Overall, radiation induces genetic instability and 
chromosomal rearrangements, and many of these rearrangements are similar to those 
found in human cancers (L. Huang, Snyder, & Morgan, 2003). 
Chronic exposure to viral infections also induce the constant generation of free 
radicals (Georgakilas, Mosley, Georgakila, Ziech, & Panayiotidis, 2010), which can 
damage cellular biomolecules, including DNA. DNA damage produced by OS results in 
apurinic/apyrimidinic (abasic) DNA sites, oxidized purines and pyrimidines, and single- and 
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double-stranded DNA breaks (Kryston, Georgiev, Pissis, & Georgakilas, 2011). 
Therefore, the ROS- and RNS-induced oxidative and nitrative DNA damage that 
frequently occurs during inflammation can contribute to carcinogenesis (Kawanishi, 
Hiraku, Pinlaor, & Ma, 2006; Ohshima, Tatemichi, & Sawa, 2003). 
A connection between OS, DNA damage and the incidence of hepatocellular 
carcinoma has been demonstrated by Hagen and colleagues (Hagen et al., 1994). The 
elevated level of ROS observed in chronic HBV-infected livers causes liver cell injury 
(Hagen et al., 1994; Shimoda et al., 1994) and may lead to an accumulation of repeated 
genetic damage and an increased risk for genomic alterations in infected hepatocytes. 
Moreover, cell necrosis and proliferation in chronic HBV infection in response to cell 
injury could allow for greater exposure of DNA to ROS and incomplete repair of DNA 
damage. All of these factors are predicted to increase the probability of the fixation of 
genetic and chromosomal abnormalities, thus causing mutations and enhancing the 
development of HCC (Hagen et al., 1994). Among the proteins encoded by HBV, the X 
gene product (HBx) is a protein that increases virus gene expression and replication to 
maintain viral infection by transactivating cellular promoters and enhancers (Feitelson et 
al., 2009; Keasler, Hodgson, Madden, & Slagle, 2007). HBx induces OS and contributes to 
liver disease pathogenesis associated with HBV infection (Waris, Huh, & Siddiqui, 2001). 
High levels of ROS can directly regulate NF-κB activation. This was 
demonstrated in EBV-positive Burkitt’s lymphoma cells, which have elevated ROS 
levels and altered NF-κB activation as opposed to EBV-negative Burkitt’s lymphoma 
cells (Cerimele et al., 2005). EBV nuclear antigen-1 is the only viral protein expressed in 
all EBV-carrying malignancies, and it induces chromosomal aberrations and DNA DSBs 
 17 
through increasing ROS production. This effect can be reversed by antioxidants (Gruhne, 
Sompallae, Marescotti, et al., 2009; Gruhne, Sompallae, & Masucci, 2009). 
As opposed to several of these other viruses, infection with HPV does not in itself 
cause significant inflammation likely to lead to OS. However, expression of the smaller 
splice variant of E6, E6*, is able to increase ROS levels in oral keratinocytes. This ROS 
level increase is likely connected to the E6*-mediated decrease in the expression of the 
antioxidant enzymes, superoxide dismutase (SOD) 2 and glutathione peroxidase (GPx) 
1/2 (Williams, Filippova, Filippov, Payne, & Duerksen-Hughes, 2014a). The increase in 
the level of oxidative stress due to E6* expression also resulted in an increase in DNA 
damage (Williams et al., 2014a). 
Other environmental and lifestyle-related factors also contribute to the induction 
of oxidative stress in infected cells. Among the factors connected to lifestyles that can 
promote virus-induced tumorigenesis are alcohol consumption and tobacco smoking. For 
example, heavy alcohol intake, defined as ingestion of more than 50–70 g/day for 
prolonged periods, is a well-established HCC risk factor (El-Serag & Rudolph, 2007). 
Alcohol-induced oxidative stress plays an important role in the development of alcohol 
liver disease, and alcohol metabolism via the enzyme alcohol dehydrogenase results in 
increased ROS production, hepatocyte injury and apoptosis. Interestingly, all of these 
reactions could be blocked by the administration of antioxidants (Adachi & Ishii, 2002; 
Bailey & Cunningham, 2002). 
Smoking is strongly associated with an increased risk of developing cervical 
cancer in HPV-positive women (Deacon et al., 2000; Plummer, Herrero, Franceschi, 
Meijer, Snijders, Bosch, de Sanjose, & Munoz, 2003). Smoking is known to induce 
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inflammation and oxidative stress (Tollefson et al., 2010), which may lead to DNA 
damage, integration and carcinogenesis, as discussed later. 
Many studies have demonstrated that long-term use of oral contraceptives 
increases the risk of cervical cancer (Appleby et al., 2007; Moreno et al., 2002; Smith et 
al., 2003). The strongest evidence for this connection comes from the large pooled 
analysis of the International Agency for Research on Cancer (IARC) studies for the role of 
oral contraceptive use in HPV-induced carcinogenesis. Although “ever use” of oral 
contraceptives was only moderately associated with cancer risk, a strong dose-response 
relationship with increasing years of use was observed (Moreno et al., 2002). 
High parity may also increase the risk of cervical cancer. One possible 
mechanism is that pregnancy maintains the transformation zone on the exocervix for 
many years (Autier, Coibion, Huet, & Grivegnee, 1996), thereby facilitating direct 
exposure to HPV and other cofactors. Hormonal changes induced by pregnancy, such as 
increased levels of estrogen and progesterone, may also modulate the immune response 
to HPV along with viral persistence and/or progression (Munoz et al., 2002; Sethi et al., 
1998). High parity may also cause cervical trauma and cellular oxidative stress, thus 
leading to DNA damage and carcinogenesis (Castellsague & Munoz, 2003). In the IARC-
pooled analysis, the odds ratio for cervical cancer in women with seven or more full-term 
pregnancies was four-fold higher than that in nulliparous women, and the risk increased 
linearly with an increasing number of full-term pregnancies (Munoz et al., 2002). 
Integration of Viral DNA into the Human Genome 
Cancer incidence is associated with integration of the viral genome for several 
oncogenic viruses, including HBV, HPV and MCV. It is not yet clear that integration of 
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EBV is a mechanism for carcinogenesis. The risk of virus integration depends on the 
level of DNA damage, because integration requires DSBs in both the host and virus DNA 
(M. Pett & Coleman, 2007) (see Figure 1). Furthermore, a major cause of DNA damage 
is OS, which can be triggered by viruses and enhanced by exogenous factors. 
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Figure 1. Integration into the host genome. Integration of HBV, HPV and MCV viral 
DNAs into the human genome induces cellular and viral responses and further contributes 
to carcinogenesis (HBV, hepatitis B virus; HPV, high-risk human papillomaviruses; MCV, 
Merkel cell polyomavirus; MCC, Merkel cell carcinoma; TERT, telomerase reverse 
transcriptase; MLL4, Mixed-lineage leukemia 4).  
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Hepatitis B Virus (HBV) 
HCC is the fifth most common cancer and the third leading cause of cancer death 
worldwide (El-Serag & Rudolph, 2007), and up to 80% of HCC is attributable to either 
HBV or HCV infection (Perz, Armstrong, Farrington, Hutin, & Bell, 2006). HBV is a 
partially double-stranded DNA hepadnavirus with retroviral features. The risk of HCC is 
increased five- to 15-fold in chronic HBV carriers compared with the general population 
(El-Serag & Rudolph, 2007), and studies have shown that integration of the HBV genome 
into the cellular genome is present in over 85%–90% of HBV-related HCCs. However, the 
integrated form of HBV is also present in non-tumor tissue of patients with chronic HBV 
infections. Integration of the HBV genome into hepatocytes occurs during persistent 
HBV infection and precedes development of HCC (Brechot, Pourcel, Louise, Rain, & 
Tiollais, 1980; Shafritz, Shouval, Sherman, Hadziyannis, & Kew, 1981). HBV 
integration leads to the elevated expression of several cellular cancer-related genes, such 
as TERT, mixed-lineage leukemia 4 (MLL4) (MLL4 is a part of the ASC-2 complex 
implicated in the p53 tumor suppressor pathway (J. Lee et al., 2009)) and CCNE1 (encoding 
cyclin E1) (Sung et al., 2012). HBV integration is also associated with early onset of HCC 
and poor outcomes (Sung et al., 2012), and integrated HBV sequences encoding the HBx 
and/or truncated envelope pre-S2/S proteins are found in a large percentage of HCC (Tsai 
& Chung, 2010). Integration of the HBx sequence into host DNA in HCC promotes 
genetic instability through mechanisms that include the inactivation of the UV-damage 
DNA binding protein, so as to interfere with nucleotide excision repair, repression of 
p53-mediated gene transcription (S. G. Lee & Rho, 2000) and inactivation of p53-
dependent apoptosis, cell cycle regulation, DNA repair and tumor suppression 
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(Kremsdorf, Soussan, Paterlini-Brechot, & Brechot, 2006). In addition, HBx 
transactivates several signaling pathways connected to carcinogenesis, including those 
mediated by protein kinase C, JAK/STAT and PI3K. (Feitelson & Lee, 2007; Feitelson et 
al., 2009). HBx also upregulates TGF-β expression in HCC tissue and is thought to 
contribute to carcinogenesis through this mechanism, as well (Yoo et al., 1996). TGF-β is 
a cytokine that inhibits hepatocyte proliferation during liver regeneration (Braun et al., 1988; 
Fausto & Mead, 1989; Nakamura et al., 1985) and stimulates extracellular matrix protein 
production by hepatocytes during liver cirrhosis (Czaja et al., 1989; Nakatsukasa et al., 
1990). Deletion of the preS2 region of the S2/S protein during HBV integration leads to a 
truncated envelope pre-S2/S protein that is frequently found in HCC samples (Tai, Suk, 
Gerlich, Neurath, & Shih, 2002) (see Figure 1). This truncated pre-S2/S product increases 
malignant transformation by transactivating several cellular genes, including c-myc, c-fos 
and c-Ha-ras (Luber et al., 1996; Schluter, Meyer, Hofschneider, Koshy, & Caselmann, 
1994). Interestingly, the pre-S mutant large surface antigens can be retained in the 
endoplasmic reticulum and, thus, escape detection by the immune system. Moreover, this 
protein can initiate ER stress and thereby induce oxidative DNA damage and genomic 
instability (H. C. Wang, Huang, Lai, & Su, 2006). The pre-S mutant also can upregulate 
COX-2 and cyclin A to induce cell-cycle progression and proliferation of hepatocytes (H. 
C. Wang et al., 2006). Overall, the process of HBV integration induces additional genetic 
alterations, including chromosomal deletions, translocations, fusion of transcripts, 
amplification of DNA and generalized genomic instability (Bonilla Guerrero & Roberts, 
2005; Feitelson & Lee, 2007), leading to overexpression of oncogenes, depletion of 
tumor suppressor genes and an altered microRNA profile (Feitelson & Lee, 2007). 
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The integration rate of HBV DNA into the host genome is significantly increased 
in the presence of DSBs (Bill & Summers, 2004). If DNA damage is induced by the 
addition of H2O2, which increases cellular levels of ROS, the frequency of HBV 
integration also increases significantly (Dandri et al., 2002). Moreover, inhibiting 
poly(ADP-ribosyl)ation by adding the ADP-ribosylation inhibitor, 3-aminobenzamide, 
also leads to a significant increase in integration (Dandri et al., 2002). Poly(ADP-ribose) 
polymerase-1 (PARP-1) is an enzyme that is stimulated by DNA strand breaks caused by 
oxidative stress and other types of DNA damage and responds by carrying out poly(ADP-
ribosyl)ation. Poly(ADP-ribosyl)ation is involved in DNA damage repair processes, such 
as base excision repair and suppression of genetic recombination (Burkle, 2001; Meyer, 
Muller, Beneke, Kupper, & Burkle, 2000; Trucco, Oliver, de Murcia, & Menissier-de 
Murcia, 1998; S. Yoshida & Simbulan, 1994). 
Integration of HBV into the human genome can occur near or within fragile sites 
in genes that regulate cell signaling, proliferation and viability (Murakami et al., 2005). 
Common targets of integration include genes for human cyclin A2 (J. Wang et al., 1992), 
the PDGF receptor, calcium signaling-related genes, mixed lineage leukemia encoding 
genes, 60S ribosomal protein genes (Murakami et al., 2005), human telomerase reverse 
transcriptase (hTERT) (Horikawa & Barrett, 2001) and the retinoic acid receptor β 
(Yaginuma et al., 1987). The data produced by Next Generation Sequencing (NGS) now 
allows researchers to not only determine the sites of integration, but also to identify the 
mutations and to specify DNA damage types that contribute to carcinogenesis (Barzon, 
Lavezzo, Militello, Toppo, & Palu, 2011; S. Li & Mao, 2013). NGS studies have shown 
that HBV integrations into TERT, MLL4, CCNE1 and ANGPT1 (encoding angiopoietin 
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1) (Fujimoto et al., 2012; Jiang et al., 2012; Sung et al., 2012) can and do occur. NGS has 
also identified frequent mutations in CTNNB1 (encoding β-catenin), IRF2 (encoding 
interferon regulatory factor 2), TP53, ARID2 (subunit of the polybromo- and BRG1-
associated factor chromatin remodeling complex (Yan et al., 2005); functioning as a tumor 
suppressor gene (M. Li et al., 2011)) and ARID1A (encoding a component of the SWI/SNF 
chromatin remodeling complex) (Guichard et al., 2012; J. Huang et al., 2012; M. Li et al., 
2011). These mutations can be associated with disease etiology. For example, ARID2 
mutations are significantly enriched in HCV-associated HCC (M. Li et al., 2011), and 
ARID1A may be crucial in HCC invasion and metastasis (J. Huang et al., 2012). IRF2 
mutations have been associated with hyperploidy and high chromosomal instability 
(Guichard et al., 2012), while TP53 inactivating mutations result in an altered p53 
pathway (Guichard et al., 2012). Interestingly, CTNNB1 mutations may define a 
homogenous subtype of HCC not related to HBV infection (Guichard et al., 2012). 
Human Papillomaviruses (HPVs) 
HPVs are a group of circular, double-stranded DNA viruses that infect epithelial 
cells. More than 100 different genotypes of HPV (Calleja-Macias et al., 2005) have been 
described; of these, a subset infects the anogenital area, and within this subset, the 
individual types are classified as either high risk or low risk. High-risk HPVs can cause 
cancerous lesions, while low-risk HPVs do not (Ault, 2007). An important difference 
between high- and low-risk HPVs is that high-risk HPVs show a greater tendency to 
integrate into the host genome, thereby causing high-grade lesions and cancer, while low-
risk types are preferentially maintained as extrachromosomal circular episomes (Arends, 
Buckley, & Wells, 1998; Scheurer, Tortolero-Luna, & Adler-Storthz, 2005). 
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HPV is known to cause virtually all cases of cervical cancer, which is the second 
most common cancer in women worldwide and the fourth most common cause of cancer 
death in women worldwide (Bernard W. Stewart, 2014; Parkin & Bray, 2006). More than 
270,000 women die from cervical cancer each year, and according to 2013 data from the 
WHO, the developing world accounts for more than 85% of these cases. More than 90% 
of premalignant and malignant squamous lesions in the uterine cervix are HPV DNA 
positive (Clifford et al., 2005; zur Hausen, 1991). Moreover, HPV16, HPV18, HPV31 
and HPV33 account for 90% of all cases of cervical cancer. Among these high-risk 
HPVs, HPV type 16 is the most prevalent type and by itself accounts for more than 50% 
of all cases of cervical cancer (Liu, Tergaonkar, Krishna, & Androphy, 1999; Lowy, 
Kirnbauer, & Schiller, 1994). High-risk HPV infection is also associated with several 
other anogenital and oropharyngeal cancers. For example, it is thought to be responsible 
for more than 90% of anal cancers, 70% of vaginal and vulvar cancers, 60% of penile 
cancers and 63% of oropharyngeal cancers ("Human papillomavirus-associated cancers - 
United States, 2004-2008," 2012). 
The majority of HPV infections are spontaneously cleared by human cells (Song 
et al., 2006; Vinokurova et al., 2008). Cervical intraepithelial neoplasia (CIN) 1 lesions 
develop occasionally, but most of these lesions will be spontaneously cleared and fail to 
progress (Ostor, 1993). However, some HPV-infected women can be co-infected by other 
viruses or bacteria, then develop cervical inflammation, as noted above. The cellular 
proliferative and anti-apoptotic effects of inflammation, combined with low-level 
expression of the E6 and E7 oncogenes encoded by the episomal HPV, contribute to 
CIN1 to CIN2 progression (Williams et al., 2011). At the CIN2 stage, the generation of 
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ROS and RNS may create DSBs in both the viral and host DNA. This can then allow 
HPV to integrate into the human genome, thereby enabling overexpression of the E6 and 
E7 oncogenes, which then facilitate the transition to CIN3 and, sometimes, invasive 
carcinoma. 
The oncogenes encoded by HPV play crucial roles in carcinogenesis. Typically, 
the levels of E6 and E7 oncogene expression from episomal HPV16 are low. In vitro, 
high-level expression of HPV oncogenes from integrated HPV forms is generally 
preceded by the loss of episomal HPV (Peitsaro, Hietanen, Johansson, Lakkala, & 
Syrjanen, 2002; M. R. Pett et al., 2006). HPV-16 integration often disrupts the E2 gene 
(the E2 ORF has been identified as a preferential site of integration), resulting in 
significantly increased expression of the E6 and E7 oncoproteins due to loss of negative 
feedback control by the viral regulatory E2 protein (M. Pett & Coleman, 2007; von 
Knebel Doeberitz, 2002) (see Figure 1). Consistent with this model, transcriptional 
activity of integrated HPV-16 DNA can be suppressed by E2 proteins from the episomal 
form (Bechtold, Beard, & Raj, 2003; Hafner et al., 2008; Herdman et al., 2006; M. Pett & 
Coleman, 2007; M. R. Pett et al., 2006). 
Elevated expression of HPV oncogenes can also be achieved by the presence of 
an increased number of episomal HPV-16 copies. A high episomal HPV-16 load, 
combined with an absence of HPV-16 integration, is frequently observed in CIN, while a 
high proportion of invasive cancers contain integrated HPV-16 forms, suggesting that 
integration is an important factor in progression from high-grade lesions to invasive 
cancer and may be a potential marker for CIN progression risk assessment (Guo et al., 
2007; Hopman et al., 2004). 
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Accumulating evidence suggests that among those factors that can increase the 
risk of HPV integration are those factors that generate excessive amounts of ROS and 
RNS. Nitrative and oxidative DNA damage were found in high-risk HPV infections, 
especially nitric oxide synthase-dependent DNA damage, which is believed to play a 
critical role in inflammation-mediated cervical carcinogenesis (Hiraku et al., 2007). 
Exposure to high and sustained levels of nitric oxide (NO) will increase DNA damage 
and mutation frequencies, supporting the idea that NO is a cofactor with infection in 
cervical carcinogenesis (Wei, Gravitt, Song, Maldonado, & Ozbun, 2009). Furthermore, 
ROS and RNS have the potential to create DNA strand breaks (Wei et al., 2009; Ziech, 
Franco, Pappa, & Panayiotidis, 2011), thereby increasing HPV-DNA integration into 
cellular chromatin. As discussed above, these factors may be virus mediated (i.e., E6* 
expression) (Williams et al., 2014a), mediated through infection or co-infection 
(inflammation) or exogenously derived (Williams et al., 2011). Our laboratory has 
demonstrated that chronic oxidative stress induced by E6* expression is able to increase 
DNA damage (Williams et al., 2014a), and it has also been shown by other laboratories 
that the frequency with which foreign DNA constructs containing antibiotic resistance 
markers integrate into genomic DNA is increased by the induction of DSBs, either by 
HPV16 E6 and E7 expression or by spontaneous breakage at fragile sites in specific 
cancer cell lines (Kessis, Connolly, Hedrick, & Cho, 1996; Matzner, Savelyeva, & 
Schwab, 2003; T. Yu et al., 2005). Therefore, the rate of HPV integration seems to 
correlate with the level of DNA damage. 
A number of pathways are affected by E6 and E7 expression (zur Hausen, 2000). 
As mentioned earlier, E6 mediates the rapid degradation of p53 and activates hTERT, 
 28 
while E7 inactivates pRB. In addition, E6 binds to IRF-3 and inhibits its transcriptional 
activity, which may provide HPV with the ability to circumvent the normal antiviral 
response (Ronco, Karpova, Vidal, & Howley, 1998). E7 sequences mediate the activation 
of cyclin E, followed by the activation of cyclin A, which is required for transformation 
(Zerfass et al., 1995). In addition, the cooperative interactions between the E6 and E7 
proteins leads to cellular immortalization (Band, Zajchowski, Kulesa, & Sager, 1990; 
Munger & Phelps, 1993), likely through a combination of specific mechanisms, such as 
those noted above. In summary, the elevated expression of oncoproteins from integrated 
forms of HPV deregulates cellular proliferation, blocks apoptosis and increases genomic 
instability, all of which contribute to cellular transformation (see Figure 1). 
HPV integration sites are distributed randomly throughout the host genome, 
without a single region predominating (Wentzensen, Vinokurova, & von Knebel 
Doeberitz, 2004). However, 38% of 192 integrants were found in known common fragile 
sites (CFSs), and there was no evidence to suggest targeted disruption or functional 
alteration of critical cellular genes by the integrated viral sequences (Wentzensen et al., 
2004). However, some studies have demonstrated that high-risk HPV integration has 
occurred within or adjacent to known oncogenes, most commonly within intronic 
sequences (Ferber et al., 2003; Thorland, Myers, Gostout, & Smith, 2003; Wentzensen et al., 
2002; Wentzensen et al., 2004). For example, the region of the MYC gene at chromosomal 
band 8q24 is a frequently observed integration site in HPV18-positive cervical cancer 
(Ferber et al., 2003; Peter et al., 2006; Wentzensen et al., 2002). Recently developed 
NGS-based methods now provide a very efficient method to map HPV integration sites. 
One NGS study, for example, showed that the 3'-breakpoints of integrated HPV16 DNA 
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distribute preferentially within the early region E1-PAE segment in HPV 16. This 
indicates the importance of deregulated viral oncogene expression for carcinogenesis (Xu 
et al., 2013). Interestingly, about half of the mapped HPV16 integration sites directly 
target human cellular genes (Xu et al., 2013). These studies suggest that the insertional 
mutagenesis of the host genome may play a role in at least some cervical cancers (M. Pett 
& Coleman, 2007). However, many publications using NGS focus on identifying 
genotype and determining HPV load, rather than on identifying sites of integration 
(Conway et al., 2012; Meiring et al., 2012). Further studies are needed to identify 
integration sites, genomic mutation and DNA damage. 
Merkel Cell Polyomavirus (MCV) 
MCV is a double-stranded DNA polyomavirus, shown to be associated with 
Merkel cell carcinoma (MCC) through the use of NGS in 2008 (Feng et al., 2008). These 
tumors display MCV DNA in an integrated form within the tumor cell genomes in a 
clonal pattern, suggesting that MCV infection and integration contribute to clonal 
expansion of the tumor cells (Feng et al., 2008; Sastre-Garau et al., 2009) (see Figure 1). 
The MCV genome encodes multiple splice variants of a tumor (T) antigen protein 
complex that targets several tumor suppressor proteins, such as pRB and p53 (Shuda et 
al., 2008). One of these splice variants, the large tumor antigen, is mutated in MCV-
positive MCC tumors cells, and this selective mutation affects the cellular DNA damage 
response to prevent auto-activation of integrated virus replication, disrupt host genomic 
integrity and inhibit cellular proliferation (Demetriou et al., 2012; J. Li et al., 2013; 
Shuda et al., 2008). Several features of this virus, such as the frequent and selective 
association of MCC with MCV, integration of MCV into the host genome, the recurrent 
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pattern of conserved viral DNA sequences and the constant expression of viral 
oncoproteins are very similar to those seen in high-risk HPV-induced cervical cancer 
[55]. However, the exact role of integration in MCC carcinogenesis requires further 
study. 
Epstein-Barr Virus (EBV) 
EBV is a double-stranded DNA herpesvirus that is primarily associated with 
Burkitt’s lymphoma, nasopharyngeal carcinoma and several lymphoproliferative 
disorders (Epstein et al., 1964). Burkitt’s lymphoma appears in three main clinical 
variants—the endemic, sporadic and immunodeficiency-associated variants. EBV is 
detected in 96% of cases of endemic variant Burkitt’s lymphoma involving the jaw, 
which is the most common malignancy of children in certain areas of central Africa (zur 
Hausen et al., 1970). In contrast, EBV is rarely associated with the sporadic variant of 
Burkitt’s lymphoma, and the jaw is less commonly involved (Xing & Kieff, 2007). EBV-
associated Burkitt’s lymphoma is common in individuals lacking efficient T-cell 
function, such as AIDS patients or transplant recipients (Kieff. E, 2007). 
All Burkitt’s lymphomas have chromosomal translocations that place the MYC 
oncogene under the control of the Ig heavy chain or one of the light-chain loci, which 
induce MYC deregulation and contribute to the pathogenesis associated with Burkitt’s 
lymphoma (Kovalchuk et al., 2000; Z. Li et al., 2003; Polack et al., 1996). EBV also 
displays transformative abilities, as EBV-encoded latent genes induce B-cell 
transformation into permanent, latently-infected lymphoblastoid cell lines (LCLs) in vitro 
by altering cellular gene transcription and activating important cell-signaling pathways 
(Young & Rickinson, 2004). 
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EBV usually persists in an episomal state with multiple copies of circular DNA. 
Integration of the EBV genome into that of the host is rare and is unlikely to contribute to 
most cases of Burkitt’s lymphoma. Such integration has been only shown in several 
Burkitt’s lymphoma cell lines, such as IB4, BL-36, BL-60 and BL-137 (Delecluse, 
Bartnizke, Hammerschmidt, Bullerdiek, & Bornkamm, 1993; Jox et al., 1997; Matsuo, 
Heller, Petti, O'Shiro, & Kieff, 1984; Popescu, Chen, Simpson, Solinas, & DiPaolo, 1993; 
Wolf et al., 1993). Integrated, episomal and linear copies of EBV DNA can coexist in 
Burkitt’s lymphoma cells (Delecluse et al., 1993). EBV integration into fragile sites of the 
host chromosome is associated with partial deletion of the viral genome and generates a 
region of enhanced chromatin instability in the host cell genome (Jox et al., 1997). This 
genome instability can induce the loss of host genes, such as BACH2, which is a putative 
tumor suppressor gene, and this may contribute to lymphomagenesis (Takakuwa et al., 
2004). 
In addition to Burkitt’s lymphoma, EBV is also associated with nasopharyngeal 
carcinoma (NPC). The undifferentiated form of NPC, classified by WHO as type III, 
shows the most consistent association with EBV worldwide, especially in particular areas 
of China and south-east Asia (M. C. Yu & Yuan, 2002). An association between EBV 
and WHO types I and II NPC has also been demonstrated (Pathmanathan et al., 1995). 
Evidence of the importance of EBV integration for the development NPC is not conclusive, 
and integration of EBV was demonstrated in only a subset of studies. For example, 
integrated EBV was found in four of 17 pathologically-diagnosed, EBV-positive NPC 
biopsy samples (Kripalani-Joshi & Law, 1994). Another study showed that EBV DNA 
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was integrated into chromosomes in the EBV-positive NPC cell lines, HSB4 and H2B17-
7. However, the exact role of integration of EBV in NPC is not clear. 
Prevention and Reduction of Risk Factors for Cancers 
Knowledge of the etiology of virus-mediated carcinogenesis, the networking of 
pathways involved in the transition from infection to cancer and the risk factors 
associated with each type of cancer, all suggest prophylactic and therapeutic strategies 
that may reduce the risk of virus-mediated cancer. Prophylactic vaccination provides one 
such strategy; HPV vaccines can effectively reduce the incidence of HPV infections and 
are anticipated to correspondingly reduce the incidence of HPV-associated cancers and 
pre-cancerous lesions over the next several decades (Saslow et al., 2007). As discussed 
here, lifestyle choices also matter, and education on the risk factors associated with these 
lifestyle choices can be considered a prophylactic measure targeting cancer prevention. 
We also note factors that contribute to virus-mediated carcinogenesis, including 
integration of the viral genomes of HBV, HPV and MCV. Typically, cancer develops 
years to decades following the initial infection with HBV and HPV. This delay provides 
us with a unique opportunity for cancer interception, especially in cases where the 
tumorigenesis process requires virus integration. In these situations, approaches that 
would decrease the probability of integration are anticipated to reduce the number of cancer 
cases. Theoretically, therapeutic or dietary measures directed against oxidative stress could 
reduce oxidative stress in already infected cells (Garcia-Closas, Castellsague, Bosch, & 
Gonzalez, 2005) and thereby diminish the risk of viral integration. Dietary antioxidants 
can, in some cases, supplement the activity of endogenous antioxidants found in normal 
cells and fortify them against challenges posed by increased levels of ROS. In the case of 
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cervical cancer, studies have shown that several antioxidants, such as reduced 
glutathione, GPx, glutathione-S-transferase, SOD and antioxidant vitamins (vitamin E, 
vitamin C, lutein, beta-carotene, lycopene and zeaxanthin), are reduced in the circulation 
of cervical cancer patients (Y. T. Kim et al., 2004; Manju, Kalaivani Sailaja, & Nalini, 
2002). In contrast, the concentration of the lipid peroxidation parameter, malondialdehyde, 
was significantly higher in women with CIN or invasive cervical cancer (Y. T. Kim et al., 
2004). That may be due to the increased utilization of the antioxidants to scavenge 
oxidative stress-induced lipid peroxidation and their sequestration by tumor cells. A 
deficiency in antioxidant vitamins may, therefore, contribute to the increased prevalence of 
cervical cancer observed in women with a low socioeconomic status (Manju et al., 2002). 
Possible benefits from dietary antioxidant consumption, a highly researched topic for the 
last two decades, still remain debatable (Halliwell, 2007; Manda, 2009). In addition, 
clinical trials addressing the effect of antioxidant therapies on cancer have not yet 
provided a clear answer (Bjelakovic, Nikolova, Simonetti, & Gluud, 2004). Future 
development of therapies for the reduction of cellular oxidative stress must take into 
account the complexity of problems inherent in the regulation of redox balance. 
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CHAPTER TWO 
CHRONIC OXIDATIVE STRESS INCREASES THE INTEGRATION 
FREQUENCY OF FOREIGN DNA AND HUMAN PAPILLOMAVIRUS 16 IN 
HUMAN KERATINOCYTES 
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Abstract 
Cervical cancer is the second most common cancer, and the fourth most common 
cause of cancer death in women worldwide. Nearly all of these cases are caused by high-
risk HPVs (HR HPVs), of which HPV16 is the most prevalent type. In most cervical 
cancer specimens, HR HPVs are found integrated into the human genome, indicating that 
integration is a key event in cervical tumor development. An understanding of the 
mechanisms that promote integration may therefore represent a unique opportunity to 
intercept carcinogenesis. To begin identifying these mechanisms, we tested the 
hypothesis that chronic oxidative stress (OS) induced by virus- and environmentally-
mediated factors can induce DNA damage, and thereby increase the frequency with 
which HPV integrates into the host genome. We found that virus-mediated factors are 
likely involved, as expression of E6*, a splice isoform of HPV16 E6, increased the levels 
of reactive oxygen species (ROS), caused oxidative DNA damage, and increased the 
frequency of plasmid DNA integration as assessed by colony formation assays. To assess 
the influence of environmentally induced chronic OS, we used L-Buthionine-sulfoximine 
(BSO) to lower the level of the intracellular antioxidant glutathione. Similar to our 
observations with E6*, glutathione depletion by BSO also increased ROS levels, caused 
oxidative DNA damage and increased the integration frequency of plasmid DNA. 
Finally, under conditions of chronic OS, we were able to induce and characterize a few 
independent events in which episomal HPV16 integrated into the host genome of cervical 
keratinocytes, using the APOT (Amplification of Papillomavirus Oncogene Transcripts) 
approach. Our results demonstrate the chain of events leading from induction of oxidative 
stress, to DNA damage, to viral integration, and ultimately to carcinogenesis. 
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Introduction 
Cervical cancer is the second most common cancer in women, and the fourth most 
common cause of cancer-related death in women worldwide (Bernard W. Stewart, 2014; 
Parkin & Bray, 2006). Human papilloma virus (HPV) infection is well-established as the 
causative agent of cervical cancer (Ahn et al., 2003), and at least 85% of premalignant 
and 90% of malignant squamous lesions in the uterine cervix test HPV DNA positive 
(Smith et al., 2007). High-risk HPV such as HPV type 16 is the most prevalent type and 
accounts for more than 50% of all cases of cervical cancer (Lowy et al., 1994). 
Over-expression of the HR E6 and E7 oncoproteins are considered responsible for 
most malignancies. This over-expression can be triggered by several mechanisms, 
including epigenetic modifications of the HPV genome (Szalmas & Konya, 2009). 
However, integration of the HPV genome into that of the host, with an accompanying 
loss of E2 and the resulting over-expression of E6 and E7, appears to be one of the most 
common oncogenic pathways (Baker et al., 1987). Following viral infection, the HPV 
genome is present in episomal form, with low levels of E6 and E7 oncoprotein expression 
due to the suppressive activity of E2 (M. Pett & Coleman, 2007). The level of oncogene 
expression grows with increase of virus load (Rosty et al., 2005) and following 
integrative events that disable E2-mediated suppression of E6 and E7 (M. Pett & 
Coleman, 2007). Clinical data support this sequence, as precancerous lesions CIN1 and 
CIN2 display episomal viral genomes (Cullen, Reid, Campion, & Lorincz, 1991), while 
rapid progression of CIN lesions is closely associated with integrated HPV16 (Peitsaro, 
Johansson, & Syrjanen, 2002) and is accompanied by increased levels of E6 and E7 
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expression. In 88% of specimens obtained from cervical cancers, HPV DNA is found 
integrated into host genomes (Klaes et al., 1999). 
Integration requires linearization of the viral genome and breakage of the host 
genome, along with the ability to re-ligate the ends together. Therefore, agents that cause 
DNA breakage are predicted to increase integration frequency. Perhaps the most common 
agents of DNA damage are reactive oxygen radicals (ROS). Indeed, in the case of 
hepatitis B virus (HBV), oxidative stress (OS) has been shown to enhance viral 
integration by increasing DNA damage (Dandri et al., 2002; Petersen, Dandri, Burkle, 
Zhang, & Rogler, 1997); this integration then serves as a key step during HBV-initiated 
carcinogenesis (Cougot, Neuveut, & Buendia, 2005). OS can be generated both by the 
virus itself and through environmental agents. Virus infection alone has the potential to 
induce OS, as seen in cases such as HBV and Epstein-Barr virus (EBV) (Cerimele et al., 
2005; Y. Chen, Williams, Filippova, Filippov, & Duerksen-Hughes, 2014; Hagen et al., 
1994; Shimoda et al., 1994). In contrast to the situation seen with these two viruses, 
infection with HPV does not in itself seem to cause significant inflammation likely to 
lead to OS, suggesting that any connection between HPV and OS is likely mediated by 
specific proteins. Support for a connection between specific HPV proteins and 
integration, possibly mediated by increased OS, is provided by the observation that 
expression of HR HPV E6 and E7 can promote integration of a reporter plasmid (Kessis 
et al., 1996). Previous work from our laboratory demonstrated that at least one HPV-
encoded protein, E6*, is able to increase ROS levels and DNA damage (Williams, 
Filippova, Filippov, Payne, & Duerksen-Hughes, 2014b). E6* is a splice variant of E6; 
interestingly, the full-length E6 protein does not affect ROS levels in the host cell 
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(Williams et al., 2014b). We also showed that an E6*-mediated increase in ROS is 
connected to a decrease in the expression of antioxidant enzymes such as superoxide 
dismutase (SOD2) and glutathione peroxidase (GPx ½) (Williams et al., 2014b). 
In addition to such viral contributions to OS, environmental contributions are also 
likely. For example, epidemiological data link conditions known to cause oxidative stress 
and DNA damage, such as smoking and co-infection with the STD-associated pathogens 
Chlamydia trachomatis and Neisseria gonorrhoeae, with increased incidence of HPV-
mediated cancers (Castle & Giuliano, 2003; Castle et al., 2001; Deacon et al., 2000; 
Finan et al., 2006; Hawes & Kiviat, 2002; Plummer, Herrero, Franceschi, Meijer, 
Snijders, Bosch, de Sanjose, & Munoz, 2003; Williams et al., 2011), while corroborating 
data from the Ozbun lab demonstrated that tobacco exposure increased E6/E7 oncogene 
expression, DNA damage and mutation rates in cells carrying HPV episomes (Wei, 
Griego, Chu, & Ozbun, 2014), and that nitric oxide increases DNA damage in HPV 
positive cells (Wei et al., 2009). 
However, the mechanistic link between OS and HPV DNA integration has not yet 
been examined, leading us to ask if we could induce HPV integration by generating OS-
induced DNA damage. To investigate the relationship between chronic OS, DNA 
damage, and the rate at which episomal HPV DNA integrates into the cellular genome, 
we first performed a validation study using a U2OS cell line model and found that 
overexpression of E6* increased the rate of circular plasmid DNA integration, while 
manipulating the level of OS modified the integration frequency. We were also able to 
demonstrate the relationship between OS induction, DNA damage and increased plasmid 
integration in Normal Oral Keratinocytes (NOK cells). Finally, by treating Human 
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Cervical Keratinocytes (HCK, which normally carry the HPV episome) with the 
glutathionine-depleting agent L-Buthionine-sulfoximine (BSO), we were able to increase 
the rate at which the HPV episome integrated into the genomic DNA. In summary, we 
found that chronic OS, caused either by E6* overexpression or by BSO treatment, 
increased the levels of cellular DNA damage, leading to an increased frequency of 
integration for plasmid and episomal HPV16 DNA. 
Materials and Methods 
Reagents 
L-Buthionine-sulfoximine (BSO) was purchased from Sigma-Aldrich (St. Louis, 
MO). Stock solution, at a concentration of 100 mM, was prepared in phosphate-buffered 
saline (PBS) and kept at -20°C. Vitamin E and Resveratrol were purchased from Sigma-
Aldrich (St. Louis, MO). Flag-agarose and anti-Flag-HRP antibodies were purchased 
from Sigma-Aldrich (St. Louis, MO). 
Cell Culture 
U2OS cells derived from a human osteosarcoma were obtained from the ATCC 
(Manassas, VA), and were cultured in McCoy’s 5A medium (Invitrogen, Carlsbad, CA) 
that was supplemented to contain 10% fetal bovine serum (FBS) (Invitrogen). The U2OS 
cell line was authenticated by ATCC short tandem repeat profiling in November, 2015 
and exhibited no evidence of cross-contamination with known ATCC cell lines. 
Normal oral keratinocytes (NOKs), non-transformed cells immortalized by 
Human Telomerase Reverse Transcriptase (hTERT) that were kindly provided by Dr. 
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Karl Münger (Piboonniyom et al., 2003), were grown in keratinocyte serum-free medium 
(Invitrogen, Carlsbad, CA).  
Human cervical keratinocytes (HCK) containing episomal HPV16, , kindly 
provided by Dr. Aloysius J. Klingelhutz (Sprague et al., 2002), were grown in E-media 
(Wu et al., 1982). 
All media were supplemented with penicillin (100 U/ml) and streptomycin (100 
μg/ml) (Sigma-Aldrich, St. Louis, MO). 
Transfections and Transductions 
Transfections were performed following the protocol provided with the TransIT-
2020 reagent kit (Mirus Bio, Madison, WI). Briefly, U2OS or NOK cells were 
transfected with plasmids encoding E6* (pE6*), E6 large (pE6 large) or the empty vector 
(pFlag). To normalize for transfection efficiency, pMetLuc was co-transfected, following 
the protocol provided with the TransIT-keratinocyte transfection reagent kit (Mirus Bio, 
Madison, WI). Expression of MetLuc was monitored in the media, and these values used 
for normalization. 
Stable clones were obtained by transduction of retroviruses pLNCX, pLNCX-
E6*, or pLNCX-E6 into NOK cells. Individual selected clones were analysed for protein 
expression by immunoblotting and/or real-time PCR as described previously (Williams et 
al., 2014b).  
Clonegenic Assay 
5×105 cells were transfected with pMetluc and incubated for 48 hours under cell 
culture conditions, followed by the addition of appropriate antibiotics (G418 at a 
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concentration of 0.5 mg/ml for U2OS cells or puromycin at a concentration of 5 μg/ml for 
NOK cells) and selection for 2-3 weeks. After antibiotic selection, colonies were fixed 
using 10% formaldehyde for 30-45 min. After rinsing with water and drying overnight at 
room temperature, cells were stained with 1% crystal violet for 45-60 min. Dishes were 
rinsed with water and left to dry overnight at room temperature. Colonies were counted 
the following day. 
Immunoprecipitation 
106 cells from each assessed U2OS preparation, transiently transfected with 
plasmids encoding E6* (pE6*), E6 large (pE6L) or vector (pFlag), were lysed using lysis 
buffer (Filippova, Song, Connolly, Dermody, & Duerksen-Hughes, 2002). Flag-tagged 
proteins were then precipitated using Flag-agarose, and bound proteins were subjected to 
SDS-PAGE. Following transfer to a polyvinylidene difluoride (PVDF) membrane, the 
Flag-E6* and Flag-E6 proteins were detected by immunoblotting using anti-Flag-HRP 
antibodies (Williams et al., 2014b). 
Flow Cytometry Assessment of ROS 
Cellular levels of hydrogen peroxide and hydroxyl and peroxyl radicals (H2O2, 
OH-, and ROO-) were measured following staining with 5-(and-6)- carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (DCFDA) (Invitrogen, Carlsbad, CA), while cellular 
levels of superoxide (O2-) were measured following staining with dihydroethidium 
(DHE) (Invitrogen, Carlsbad, CA) (Peshavariya, Dusting, & Selemidis, 2007). Stock 
solutions (20 mM) of the dyes were diluted with culture medium and added to cells to a 
final concentration of 5 μM DCFDA or 5 μM DHE. After incubating at 37°C in the dark 
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for 30 min, cells were trypsinized, washed, and collected using PBS. The DCFDA and 
DHE signals were detected in the FL-1 (530 nm) and FL-2 channels (650 nm) 
respectively with a Becton, Dickinson FACS Calibur flow cytometer (BD, Franklin 
Lakes, NJ). A total of 10,000 events were measured per sample. Data were collected and 
analysed using CellQuest Pro and FlowJo software (Williams et al., 2014b). 
Glutathione Levels 
To assess the level of intracellular glutathione, cells were seeded into 96-well cell 
culture plates and allowed to grow for 24 hours under cell culture conditions. Cells were 
then treated with the BSO for 48 hours. Intracellular glutathione levels were measured 
using the bioluminescent Promega GSH-Glo™ glutathione assay kit according to the 
manufacturer’s protocol (Promega, Madison, WI). Luminescence was detected using a 
MicroLumat Plus LB 96V bioluminometer (Berthold Technologies, Oak Ridge, TN). 
Comet Assessment of DNA Damage 
The comet assay was performed following the protocol provided with the 
Trevigen kit (Trevigen, Gaithersburg, MD). Briefly, cells were plated in agarose and 
spread over the sample area on slides. Alkaline electrophoresis using 21 V for 40 min 
was then performed. Nuclei were stained with SYBR gold (Invitrogen, Carlsbad, CA) 
and viewed by fluorescence microscopy. 100 DNA tails were photographed and analysed 
for each sample, and the length of each tail was measured from the center of the comet to 
the end of the tail using ImageJ software. Each cell was categorized as having tail lengths 
in one of four classes (0 to 50, undamaged; 50 to 100, minimum damage; 100 to 150, 
medium damage; >150, maximum damage) reflecting the severity of DNA damage. Tail 
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lengths are known to increase proportionately with DNA damage (Williams et al., 
2014b).  
APOT (Amplification of Papillomavirus Oncogene Transcripts) 
The APOT assay was applied to detect and distinguish episomal- and integration-
derived HPV transcripts. RNA from 5×106 cells was isolated using a Direct-zol RNA 
MiniPrep kit (Zymo research, Irvine, CA) as recommended by the supplier. Total RNA (1 
mg) was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystem by Life Technologies, Grand Island, NY), using an oligo(dT)17-
primer coupled to a linker sequence [(dT)17-p3, 5’-
GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT-3’] and 1 μl of MultiScribe 
reverse transcriptase for 10 min at 25°C, then for 120 min at 37°C in a final volume of 20 
μl.  
APOT was performed as described previously by Klaes et al (Klaes et al., 1999). 
Briefly, cDNAs were amplified by the first PCR round using HPV E7-specific 
oligonucleotides [p1 specific for HPV16 (5’-CGGACAGAGCCCATTACAAT-3’) as 
forward primers and p3 (5’-GACTCGAGTCGACATCG-3’) as the reverse primer] in a 
50 μl reaction mixture. The second PCR used forward primers p2 specific for HPV16 (5’-
CTTTTTGTTGCAAGTGTGACTCTACG-3’) and (dT)17-p3 as the reverse primer in a 
total volume of 50 μl reaction mixture.  
Amplification products were visualized by 1% agarose gel electrophoresis, and 
amplicons of sizes other than the episome-derived transcript (1050 bp) were subjected to 
further analysis (Klaes et al., 1999). PCR bands were extracted and cloned into pTOPO 
using the TOPO cloning reaction kit (Life Technologies, Grand Island, NY) and 
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sequenced. The sequences obtained were compared to those within the HPV16 and 
human genomes to identify similar sequences, using National Center for Biotechnology 
Information (NCBI) Blast as well as UCSC Genome Bioinformatics Blat tools.  
Quantitative Reverse Transcription PCR (qRT-PCR) 
Reverse transcription was performed as described above (APOT). Quantitative 
real-time PCR was conducted to measure the levels of the E6 isoforms using primers 
designed as described previously by Hafner et al. (Hafner et al., 2008), along with an 
Absolute QPCR SYBR Green Kit according to the manufacturer’s protocol (Bio-Rad 
Laboratories, Hercules, CA). The observed E6 isoform concentrations were normalized 
using the level of phosphoglycerokinase (PGK) expression. 
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Results 
E6*, but not E6, Increased the Level of OS and the Integration Frequency of Plasmid 
DNA into U2OS Cells 
Previously, we demonstrated that overexpression of E6*, but not of the full-length 
E6 isoform, caused increased cellular levels of ROS and higher levels of oxidative DNA 
damage (Williams et al., 2014b). To investigate whether overexpression of E6* also 
increases the rate at which circular plasmid DNA integrates into the human genome, we 
performed a clonogenic assay. U2OS cells were transfected with plasmids encoding one 
of the HPV 16 E6 isoforms, E6* (pE6*) or the full-length E6 (pE6L), or with the empty 
vector (pFlag), along with a plasmid coding for G418 resistance. To normalize for 
transfection efficiency, the pMetLuc plasmid was co-transfected, and the expression of 
Metridia luciferase was monitored in the media. After G418 selection, the remaining 
colonies were stained with crystal violet and counted (Figure 2A). The normalized 
number of colonies is presented in Figure 2B. These data show that the number of 
colonies was higher when cells were transfected with pE6* than when transfected with 
the vector or the pE6 large plasmids (Figure 2A and B). Immunoprecipitation followed 
by immunoblot analysis showed that E6* and E6 large were expressed in the 
corresponding cells (Figure 2C), and ROS levels following transient transfection with 
these plasmids, as estimated by fluorescence following DCFDA staining, were higher in 
cells transfected with E6* when compared to those transfected with pFlag or pE6L 
(Figure 2D). Overall, these results demonstrate that the short variant of the HR HPV E6 
oncoprotein, E6*, but not the full-length variant (E6L), induces an increase in ROS and 
promotes the integration of plasmid DNA. 
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Figure 2. E6*, but not E6, increased the level of OS and the integration frequency of 
plasmid DNA into U2OS cells. (A) and (B) 106 U2OS cells per well were co-transfected 
with plasmids encoding E6* (pE6*), E6 (pE6L) or vector (pFlag) together with the 
pMetLuc puro plasmid. To normalize for transfection efficiency, the media was collected 
48 h post-transfection and the expression of secreted MetLuc (BD Clontech) was measured. 
Selection of cells resistant to G418 (0.5 mg/ml) was performed for 3 weeks and the 
resulting colonies were stained with crystal violet. Colonies were counted after crystal 
violet staining (A) and normalized for transfection efficiency (B). (C) Immunoprecipitation 
followed by immunoblot shows expression of Flag-E6* and Flag-E6L proteins after 
transient transfection. (D) 105 cells per well of U2OS cells were transfected with plasmids 
encoding E6* (pE6*), E6 (pE6L) or vector (pFlag), and the level of cellular ROS level was 
analysed 48 h post-transfection by fluorescence using a fluorescence plate reader following 
DCFDA staining. Triplicate measurements of mean fluorescence intensity of DCFDA were 
performed to generate the bar graphs of % mean fluorescence, setting the pFlag mean 
fluorescence at 100%. 
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Increasing ROS Results in Increased Integration Frequency, while Decreasing ROS 
Results in Decreased Integration Frequency 
To examine the impact of OS on integration frequency, we increased or decreased 
the levels of ROS using agents known to affect cellular levels of these reactants. To carry 
out this set of experiments, we needed an agent that would induce chronic OS in our cells 
by modulating ROS levels without significantly affecting cell viability. We found that L-
Buthionine-sulfoximine (BSO), which decreases the level of glutathione in cells through 
inhibition of gamma glutamyl cysteine synthetase (gamma GCS), the enzyme that 
catalyzes the first step of glutathione synthesis (Armstrong et al., 2002), was suitable for 
our needs. Application of BSO to U2OS cells at doses from 1.25 μM to 80 μM did not 
significantly affect cell viability, as assessed by crystal violet staining (Figure 3A), while 
treatment with 5 and 10 μM of BSO for 48 hours led to elevation of ROS levels, as 
assessed by flow cytometry following DCFDA staining (Fig, 3B).  
To determine whether chronic OS induced by BSO treatment increases the 
integration frequency of plasmid DNA in U2OS, we performed a clonogenic analysis of 
U2OS cells transfected with the pcDNA3 plasmid. After transfection, cells were plated 
onto a 6-well plate, and 3 wells were treated with 5 μM BSO for 5 days while the 
remaining 3 wells were used as controls. Following G418 selection, the colonies were 
stained with crystal violet and counted (Figure 3C). The normalized number of colonies 
is presented in Figure 3D. These results demonstrate that chronic OS induced by BSO 
promotes the integration of plasmid DNA into U2OS cells.  
To assess the effect of decreased ROS levels on integration frequency, cells were 
treated with the known antioxidants resveratrol (Leonard et al., 2003) and vitamin E 
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(Herrera & Barbas, 2001), and integration frequency was estimated using the clonogenic 
assay as described above. As expected, we found that ROS levels were significantly 
decreased after treatment with 5 μM and 10 μM resveratrol (Figure 3E) or with 10 μM 
Vitamin E (Figure 3F) for 48 hours as assessed by flow cytometry following DCFDA 
staining. After transfection with the pcDNA3 plasmid carrying the G418-resistant gene, 
cells were plated onto a 6-well plate, and 3 wells were treated with 10 μM resveratrol for 
48 hours while the remaining 3 wells were left untreated. Following G418 selection, the 
colonies were stained with crystal violet and counted (Figure 3G). A similar experiment 
was performed with U2OS cells treated with 10 μM Vitamin E (Figure 3H). These results 
clearly demonstrate that antioxidants that decreased ROS levels also caused a reduction 
in the rate at which circular plasmid DNA integrated into U2OS cells. 
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Figure 3. Increasing ROS results in increased integration frequency, while decreasing ROS 
results in decreased integration frequency. (A) U2OS cells (104 cells per well) were plated 
onto a 96 -well plate, and cells were treated with BSO in triplicate at the indicated 
concentrations for 48 hours. Cell viability was estimated using the crystal violet assay. Cell 
viability without BSO treatment was set at 100%. (B) The level of ROS in U2OS cells 
treated with the indicated concentrations of BSO for 48 h was estimated by flow cytometry 
following DCFDA staining. (C) 1.5 x 105 cells per well of U2OS were transfected with the 
pcDNA3 plasmid, then plated onto a 6 well plate. After 24 hrs, 3 wells were treated with 5 
μM of BSO for 5 days. Selection of cells resistant to G418 (0.5 mg/ml) was performed for 
approximately 2 weeks, following which the colonies produced were stained with crystal 
violet. Colony numbers are presented in the bar graph (D). (E) and (F) The level of ROS 
in U2OS cells treated with the indicated concentrations of resveratrol (E) and vitamin E 
(F) for 48 h was estimated by flow cytometry following DCFDA staining. (G) and (H) 1.5 
x 105 cells per well of U2OS were transfected with the pcDNA3 plasmid, then plated onto 
a 6 well plate. After 24 hrs, 3 wells were treated with 10 μM of resveratrol (G) or 10μM of 
Vitamin E (H) for 48 h. Selection of cells resistant to G418 (0.5 mg/ml) was performed for 
approximately 1 week, and the colonies produced were stained with crystal violet. Colony 
numbers are presented in the corresponding bar graphs (G) and (H). Error bars represent 
the standard deviation, * represents a 0.95 level of confidence, ** represents a 0.99 level 
of confidence, and *** represents a 0.999 level of confidence. 
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OS, Induced by either Overexpression of E6* or by Glutathione Depletion, Increases 
DNA Damage and the Frequency of Plasmid DNA Integration into NOK Cells 
To determine whether an increase of ROS in keratinocytes, the natural target cells 
for HPV infection, also results in an increased rate of circular DNA integration, we 
employed Normal Oral Keratinocytes (NOK), a cell line which was immortalized using 
hTERT (gift of Karl Münger) (Piboonniyom et al., 2003). NOK cells stably expressing 
either E6* alone, E6, or the empty vector control were obtained as described previously 
following transduction of the retroviruses pLNCX-E6*, pLNCX-E6 or pLNCX, 
respectively (Williams et al., 2014b). We first compared the level of E6* expression in 
NOK-derived pE6*, pE6L and pLNCX cells with that seen in CaSki and SiHa cells, 
where E6* is expressed from integrated HPV16 (Meissner, 1999), and with the level of 
E6* expressed in human cervical keratinocytes (HCK) using qRT-PCR. The level of E6* 
expression in NOK pE6* cells was approximately 2 times higher than that observed in 
HCK and CaSki cells, suggesting that the level of E6* expression from the estimated 50-
100 copies of the HPV genome in HCK cells is comparable to that seen from the 
integrated HPV in CaSki cells, and that expression of E6* from the E6*-expressing NOK 
cells is well within a two-fold range of levels seen physiologically (Figure 4A).  
NOK cells expressing E6* are characterized by higher levels of ROS (Figure 4B) 
and DNA damage (Williams et al., 2014b) than seen in NOK pLNCX or NOK E6L cells. 
To determine whether the plasmid integration rate was also higher in these cells, we 
transfected these pLNCX-E6*, pLNCX-E6 and pLNCX cells with the plasmid pMetLuc 
puro. To normalize for transfection efficiency, expression of secreted luciferase in the 
media was monitored. After puromycin selection, the number of colonies was counted 
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after crystal violet staining (Figure 4C). This clonogenic assay revealed that NOK cells 
expressing E6* produced a higher number of colonies, as compared to NOK cells 
expressing either E6 or those transfected with the empty vector. These results 
demonstrate that overexpression of E6* results in an increase in ROS along with 
enhanced DNA integration into keratinocytes, similar to our observations in the U2OS 
model system. 
To assess the impact of external, OS-inducing agents on DNA damage and 
integration in NOK cells, we again employed BSO. We found that BSO at concentrations 
ranging from 5 μM to 20 μM does not affect cell viability, as assessed by crystal violet 
staining (Figure 4D). We also measured glutathione levels in these NOK cells before and 
after BSO treatment for 48 hours at several concentrations (5, 10, 20, and 40 μM) using 
the glutathione assay (Promega, Madison, WI). Figure 4E shows that BSO does, indeed, 
significantly reduce the level of glutathione in treated cells as compared to that seen in 
untreated cells. Treatment with BSO for 48 hours at concentrations of 12 and 100 μM in 
NOK cells increased ROS levels significantly (Figure 4F), as assessed by flow cytometry 
following DCFDA staining. Together, these results show that BSO is capable of inducing 
chronic cellular OS by decreasing levels of the antioxidant glutathione, without 
significantly affecting cell viability.  
Next, we asked whether chronic OS induced by long-term BSO treatment would 
also increase DNA damage. NOK cells were treated with BSO for 9 days at a 
concentration of 5 μM, and DNA damage was estimated using the comet assay. The 
comet assay detects DNA strand breaks by measuring the distance DNA migrates out of 
cells (tail lengths), which corresponds to the severity of DNA damage (Collins, 2004). 
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The results of the comet assay (Figure 4G) demonstrate that the number of cells with 
longer tail lengths is increased in BSO-treated cells, as compared to an untreated control 
group. Representative cells with and without BSO treatment are shown in Figure 4H.  
To determine whether chronic OS induced by BSO treatment also increases the 
integration frequency of plasmid DNA in keratinocytes, we performed a clonogenic 
analysis of NOK cells transfected with the pMetLuc puro plasmid. After transfection, 
cells were plated onto a 6-well plate, and 3 wells were treated with BSO for 48 hours 
while the remaining 3 were used as controls. Following puromycin selection of treated 
and untreated cells, the colonies were stained with crystal violet. No puromycin resistant 
clones were observed in wells without BSO treatment, while numerous stable clones 
were noted in wells treated with BSO (Figure 4I). These results clearly demonstrate that 
chronic OS induced by BSO promotes the integration of plasmid DNA.  
The chronic OS that increased integration rates in NOK cells was induced by 
either overexpression of E6* (Figure 4C) or BSO treatment (Figure 4I). We compared the 
cellular levels of ROS resulting from E6 and E6* expression with those observed 
following treatment with 10 μM BSO. The results shown in Figure 4B demonstrate that 
exogenous application of the glutathione depleting agent BSO and expression of E6* in 
NOK cells lead to comparable levels of OS, suggesting that both environmental and viral 
factors may make significant contributions to the overall oxidative status. 
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Figure 4. OS, induced by either overexpression of E6* or by glutathione depletion, 
increases DNA damage and the frequency of plasmid DNA integration into NOK cells. (A) 
The expression levels of E6* transcripts in HCK, CaSki, SiHa, and NOK cell lines stably 
expressing either E6* alone (pE6*), E6 large (pE6L), or the empty vector (pLNCX) were 
analysed by qRT-PCR. E6* transcript expression levels were normalized by PGK gene 
expression. (B) ROS levels in NOK-derived stable cell lines and NOK treated with 10 μM 
BSO were analysed by flow cytometry using DCFDA (upper panel) and DHE (lower panel) 
as described in Material and Methods. (C) 106 cells per well of NOK-derived cell lines 
stably transduced with E6*, E6 large or the vector control were transfected with the 
pMetLuc puro plasmid. To normalize for transfection efficiency, media was collected 48 
h post-transfection and the expression of secreted MetLuc was measured. Selection of cells 
resistant to puromycin (5 μg/ml) was performed for 3 weeks, and the colonies produced 
were stained with crystal violet. (D) NOK cells (104 cells per well) were plated onto a 96 -
well plate, and cells were treated with BSO in triplicate at the indicated concentrations for 
48 hours. Cell viability was estimated using the crystal violet assay. Cell viability without 
BSO treatment was set at 100%. (E) 5x104 NOK cells were plated onto 24-well plates. 
After attachment, cells were treated with the indicated concentrations of BSO for 48 h. The 
resulting level of glutathione was measured using the Promega GSH-Glo™ glutathione 
assay kit according to the manufacturer’s protocol. Measurements were performed in 
triplicate, and the glutathione level in untreated cells was set at 100%. (F) The level of 
ROS in NOK cells treated with the indicated concentrations of BSO for 48 h was estimated 
by flow cytometry following DCFDA staining. (G) and (H) NOK cells treated or untreated 
with 5 μM of BSO for 9 days, and the DNA damage was measured using the comet assay 
as described in Materials and Methods. (G) 100 cells were counted per cell line and the 
percentage of cells with each tail length was calculated. (H) Representative comet images 
of NOK cells untreated and treated with 5 μM BSO, visualized by microscopy following 
alkaline electrophoresis. (I) 6 x106 cells were transfected with the pMetLuc puro plasmid, 
then plated onto a 6 well plate. After 24 hrs, 3 wells were treated with 100 μM of BSO for 
48 h. Selection of cells resistant to puromycin (5 μg/ml) was performed for 3 weeks and 
the resulting colonies were stained with crystal violet.  
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 OS Induced by Glutathione Depletion Increases DNA Damage in HCK Cells 
Containing Episomal HPV16 
The results described above indicate that chronic OS exogenously induced by 
BSO increases the rate at which plasmid DNA integrates into NOK cells. To determine if 
OS stress is also able to promote the integration of episomal HPV into the genome of the 
host, we employed HPV-positive human cervical keratinocytes, HCK, in which the HPV 
genome is normally maintained in an episomal state. These cells were kindly provided by 
Aloysius J. Klingelhutz (Sprague et al., 2002). First, we determined the concentration 
range of BSO that was capable of increasing ROS levels without affecting cell viability in 
HCK cells. We found that BSO concentrations within the 5 μM to 320 μM range did not 
affect viability (Figure 5A), however, such BSO treatments were accompanied by 
decreases in glutathione levels (Figure 5B). Furthermore, concentrations of 50 and 100 
μM BSO did significantly increase ROS levels in HCK cells after 48 hours of treatment 
(Figure 5C).  
DNA damage in HCK cells following treatment with 100 μM BSO treatment for 
8 days was evaluated using the Comet assay. The results presented in Figure 5D show 
that the relative number of cells with longer tail lengths was increased after BSO 
treatment, as compared to the untreated group. A representative comet assay is shown in 
Figure 5E. These results demonstrate that exogenous application of the glutathione 
depleting agent BSO can induce OS and increase DNA damage in HCK cells containing 
episomal HPV16. 
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Figure 5. OS induced by glutathione depletion increases DNA damage in HCK cells 
containing episomal HPV16. (A) 104 cells per well of HCK cells were plated onto a 96 -
well plate. Cells were treated with BSO in triplicate at the indicated concentrations for 48 
hours. Cell viability was estimated by the crystal violet assay, with cell viability without 
BSO treatment set at 100%. (B) 5 x 104 HCK cells were plated onto 24-well plates. After 
attachment, cells were treated with the indicated concentrations of BSO for 48 h. The level 
of glutathione was measured using the Promega GSH-Glo™ glutathione assay kit 
according to protocol. Measurements were performed in triplicate, and the glutathione level 
of untreated cells was set at 100%. (C) The level of ROS in HCK cells untreated or treated 
with the indicated concentrations of BSO for 48 h was estimated by flow cytometry 
following DCFDA staining. (D) and (E) HCK cells, were untreated or treated with 100 μM 
BSO for 8 days, then DNA damage was measured by the comet assay as described in 
Material and Methods. (D) 100 cells were counted per cell line and the percentage of cells 
with each tail length was calculated. (E) Representative comet images of HCK cells 
untreated or treated with 100 μM BSO, visualized by microscopy following alkaline 
electrophoresis. 
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 Chronic OS Increases the Frequency of HPV16 Genome Integration in HCK Cells 
Containing Episomal HPV16 
To determine whether the DNA damage induced by chronic OS results in an 
increase in the frequency with which the HPV episome integrates into the genome, we 
employed the Amplification of Papillomavirus Oncogene Transcripts (APOT) assay. This 
assay detects fusion forms in integrated viral oncogene transcripts (Figure 6A) (Klaes et 
al., 1999). HCK cells were treated with BSO, and samples of treated cells were collected 
at days 10 and 17. Samples of untreated cells were collected, and all samples were kept 
frozen at -80C prior to RNA isolation and performance of the assay. Results from the 
APOT assay are shown in Figure 6B. RNA isolated from CaSki and SiHa cells were used 
as controls for the integrated HPV genome, since both cell lines are known to contain 
integrated HPV16 (Meissner, 1999).  
An episomal HPV-derived transcript produces a 1050 bp product when assessed 
with a 5’-primer specific for the E7 region and a 3’-primer that binds to the poly-A tail 
region. If HPV is integrated, however, these primers will yield evidence of a fused 
transcript containing both HPV and human sequences. Hence, additional bands of 
different sizes will be observed (Klaes et al., 1999). The results of our APOT assay 
showed that PCR products from integration-derived transcripts in CaSki and SiHa cells 
were indeed of different lengths than the episomally-derived 1050 bp, showing that 
APOT detect fused transcripts (Meissner, 1999) (Figure 6B, right two lanes). In HCK 
cells untreated with BSO, however, the most abundant band was found to be 1050 bp, 
confirming our expectation and previous reports that this cell line carries the episomal 
form of the virus (Sprague et al., 2002) (Figure 6B, left-most lane). Treatment with BSO 
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for either 10 or 17 days led to the appearance of 3 additional bands of lesser size (Figure 
6B). It is worth noting that the intensity of these additional bands was stronger at day 17 
than at day 10 (Figure 6B, lane 3 vs lane 2). These results suggest that integration-derived 
HPV transcripts do appear after long-term BSO treatment, consistent with our working 
model stating that chronic OS increases DNA damage and hence episomal integration. To 
determine whether these transcripts were indeed derived from integrated HPV, these 
additional bands of less than 1050 bp were cloned and sequenced. These additional bands 
contained chimeric sequences composed of HPV viral sequences together with cellular 
sequences. Direct sequencing showed that in each case, the breakpoints in HPV occurred 
in the region of the E7 gene, while the 3 human insertions occurred within 3 separate 
genes, CUX2, JRKL-AS1, and tRNaseZL-interacting RNA B1. Together, these data 
indicate that treatment with BSO, which increased the level of OS and DNA damage in 
these episome-harboring cells, led to 3 independent integration events in which episomal 
HPV was inserted into the host genome, and support a chain of events leading from the 
induction of oxidative stress, to DNA damage, and finally, to viral integration. 
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Figure 6. Chronic OS increases the frequency of HPV16 genome integration in HCK cells 
containing episomal HPV16. (A) Scheme showing the Amplification of Papillomavirus 
Oncogene Transcripts (APOT) assay. Transcripts derived from either episomal (left) or 
integrated (right) HPV16 forms, as well as the location of primers used for the Reverse 
Transcriptase Reaction ((dT)17-p3) for PCR (p1, p2, p3) are indicated (modified from 
Ruediger Klaes, Stefan M. et al. (Klaes et al., 1999)). (B) HCK were treated with 5 µm 
BSO for 10 and 17 days. RNA from these cells, together with that from untreated cells 
(days 0) was isolated, then used to perform the APOT assay as described in Material and 
Methods. RNAs isolated from CaSki and SiHa cells were used as controls for the integrated 
HPV genome. * labels the integrated HPV genome. # labels new additional bands 
corresponding to transcripts from integrated forms of HPV16. cDNA was synthetized using 
oligo-dT, and nested PCR was performed using primers specific for E7 and poly-A.   
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Discussion 
In the work reported here, we tested the hypothesis that virus-mediated and/or 
environmental factors can induce chronic OS that contributes to DNA integration. 
Consistent with our working model, we demonstrated that indeed, chronic OS increases 
the integration rate of both plasmid DNA and the HR HPV genome. 
Integration of plasmid DNA occurs in response to OS induction, as assessed by a 
clonogenic assay (Figures 2A, 2B, Figures 3C, 3D, Figures 4C, 4I), as does HPV genome 
integration, as shown by APOT analysis (Figure 6B). These results are important because 
they demonstrate, for the first time, that the frequency of HPV integration can be 
manipulated by modulating levels of OS. It is generally accepted that high levels of ROS 
contribute to carcinogenesis by damaging DNA, RNA, proteins, and lipids, leading to 
cellular toxicity (reviewed in (Williams et al., 2011)). With respect to DNA, OS can 
induce DNA damage that results in apurinic/apyrimidinic (abasic) DNA sites, oxidized 
purines and pyrimidines, single-strand breaks (SSB) and double-strand breaks (DSB). These 
events further lead to chromosomal rearrangements and point mutations (Y. Chen et al., 
2014; Kryston et al., 2011). With regards to DNA viruses, OS is particularly important in 
the context of HPV DNA integration, as ROS and reactive nitrogen species (RNS) have 
the potential to create the DSBs (Wei et al., 2009; Ziech et al., 2011) that can in turn 
enable viral integration. Our ability to induce HPV integration provides us with a novel 
tool to experimentally study the initial steps of carcinogenesis using models that closely 
resemble an actual HPV infection. 
Among the different mechanisms of viral carcinogenesis, integration of the viral 
genome into the host genome plays a critical role during the process of transformation by 
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several oncogenic viruses including HBV, HPV, and Merkel cell polyomavirus (MCV). 
The connection between HBV integration and carcinogenesis is well accepted (Brechot et 
al., 1980; Shafritz et al., 1981), though the exact role of integration in Merkel cell 
carcinoma (MCC) carcinogenesis requires further study (reviewed in (Y. Chen et al., 
2014)). The connection between HPV integration and carcinogenesis is also widely 
accepted (M. Pett & Coleman, 2007), and is largely based on analyses of patient tumor 
samples, as such cells present with integrated HPV at a very high frequency. However, 
this focus on fully transformed tissues limits the conclusions that can be drawn regarding 
factors that influence the integration events occurring prior to tumor development. 
Studies of tumor specimens indicate a lack of targeted disruption or functional alterations 
of critical cellular genes by the integrated viral sequences. Instead, most studies agree 
that integration occurs most frequently in common fragile sites (CFSs) (Wentzensen et 
al., 2004) and in intronic sequences of human cellular genes (Xu et al., 2013) within (or 
adjacent to) oncogenes (Wentzensen et al., 2004).  
The three integration events we identified all involve a fusion between the E7 
oncogene and a cellular sequence, with none of the three representing the type of 
integration event (between E2 and a cellular sequence) often observed in tumors. We 
therefore suggest that the integration of HPV genome into the host genome may be a 
much more frequent event than the initiation of transformation, and furthermore suggest 
that in most cases, this process is random and neutral in the context of cellular 
transformation. Consistent with our findings, a study from L. Turek’s lab also shows that 
some identified HPV16 integration loci from head and neck cancer samples are involved 
in control of cell growth phenotype and oncogenes (16%), while other integration loci are 
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neutral and varied, suggesting that not every integration of the virus will lead to 
carcinogenesis. The functional role of these viral integration events in the course of 
oncogenic progression remains to be defined (Lace et al., 2011). 
Integration occurs rarely and represents a dead-end for the virus life cycle. 
However, accumulating evidence indicates that the machinery for HPV integration is 
likely provided by the HPV replication process (McKinney, Hussmann, & McBride, 
2015), by way of activating the DNA Damage Response (DDR). Several DNA viruses, 
including HPV, have been shown to activate and utilize DNA repair mechanisms to 
enhance their own replication (review (Lilley, Schwartz, & Weitzman, 2007)). This is a 
reasonable link, since there is overlap between enzymes that mediate repair and those that 
participate in DNA replication. HPV viral DNA replication occurs in the nuclear foci, 
and expression of the E1 and E2 replication proteins is sufficient for the formation of 
replication foci that recruit components of the DDR (Fradet-Turcotte et al., 2011; 
Reinson et al., 2013; Sakakibara, Mitra, & McBride, 2011; Swindle et al., 1999). HPVs 
enter the nucleus and initiate replication and transcription programs adjacent to nuclear 
domain 10 (ND10) bodies, which are associated with regions of DNA damage (Day, 
Baker, Lowy, & Schiller, 2004; Everett, 2006). Both E7 (Moody & Laimins, 2009) and 
E1 (Sakakibara et al., 2011) expression have been shown to activate the ATM-mediated 
DNA damage response. Although E6 inactivates the p53-mediated DNA damage repair 
pathway, p53-independent forms of DNA damage repair continue to function (Moody & 
Laimins, 2009) and thereby support viral replication. Following DNA damage, 
recruitment of the repair apparatus to the linear viral episome and/or breaks in the host 
genome likely occurs. The recruitment of DNA damage repair complexes ensures the 
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availability of ligases that can reconnect the recombined host and virus sequences, 
creating a microenvironment conducive to viral integration. In cases where the E1 and/or 
E2 regions are disrupted, these replication proteins are not expressed from integrated 
genomes but would be expressed from co-replicating, extrachromosomal HPV genomes, 
thereby inducing recruitment of DDR proteins to the integration loci, resulting in onion 
skin replication and promotion of genetic instability (Kadaja, Isok-Paas, Laos, Ustav, & 
Ustav, 2009; Kadaja et al., 2007). Any modification that results in increased expression 
of the E6 and E7 oncoproteins is anticipated to further stimulate genetic instability and 
promote carcinogenesis (McKinney et al., 2015). The DDR can be induced by exogenous 
factors (Giglia-Mari, Zotter, & Vermeulen, 2011) and, as noted above, is likely involved 
in HPV integration.  
In this current report, we showed that DNA damage induced through exogenous 
chronic OS increased integration of the HPV genome (Figure 5A-E, 6B). DNA damage, 
and the resulting DDR, can also be induced by virus-derived factors, as the ability to 
damage DNA has been reported for E2, E6, E6* and E7 (Bermudez-Morales et al., 2009; 
Duensing & Munger, 2002; Williams et al., 2014b). In fact, our results demonstrated that 
E6* expression can induce DNA damage through increasing ROS levels and thereby 
promote foreign DNA integration (Figures 2A, 2B, Figures 3C, 3D, Figures 4C, 4I). 
Factors other than OS can also promote integration of the viral genome. E6 and E7 
expression have been shown to induce genome instability and contribute to an increased 
integration rate (Kessis et al., 1996); in addition, viral load and persistence have been 
demonstrated to promote integration (Moberg, Gustavsson, Wilander, & Gyllensten, 
2005; M. Pett & Coleman, 2007).  
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Importantly, we were able to successfully decrease the integration frequency by 
using antioxidants (resveratrol and vitamin E). These results (Figures 3E-H) are 
significant because they suggest that if chronic OS is indeed a factor promoting HR HPV 
integration, we have the potential to develop prophylactic and therapeutic strategies 
designed to prevent this initial step in carcinogenesis. Reduction of risk factors associated 
with chronic OS should be therefore considered as a prophylactic approach for the 
prevention of cervical cancer. Theoretically, therapeutic or dietary measures aimed at 
reducing oxidative stress could decrease oxidative stress in already-infected cells (Garcia-
Closas et al., 2005), and thereby diminish the risk of viral integration. In this report, we 
used the antioxidants vitamin E and resveratrol to reduce levels of cellular oxidative 
stress, which in turn reduced the integration of foreign DNA into U2OS cells. Our 
findings suggest that dietary antioxidants may be able to supplement the activity of 
endogenous antioxidants found in normal cells and fortify them against challenges posed 
by increased levels of ROS. In fact, studies have shown that several antioxidants are 
reduced in the circulation of cervical cancer patients (Manju et al., 2002). A deficiency in 
antioxidant vitamins and/or other dietary components may, therefore, contribute to the 
increased prevalence of cervical cancer observed in women with a low socioeconomic 
status (Manju et al., 2002). Possible benefits from dietary antioxidant consumption 
remain under discussion (Garcia-Closas et al., 2005), and additional work is needed to 
test the effect of antioxidant therapies as a new approach for decreasing the probability of 
integration and thereby reducing cervical cancer incidence.  
Overall, our results demonstrate that chronic OS can induce DNA damage and 
increase the frequency of HPV integration into the host genome, and in this way 
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contribute to cervical carcinogenesis. Future strategies may focus on assessing cancer risk 
by screening for OS levels, then applying therapies directed toward OS, thereby 
decreasing the integration rate, and ultimately, carcinogenesis. 
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CHAPTER THREE 
IDENTIFICATION OF INTEGRATION SITES BY NEXT GENERATION 
SEQUENCING (NGS) BASED ANALYSIS  
 
 
Introduction 
Previously, we had employed the Amplification of Papillomavirus Oncogene 
Transcripts (APOT) method to identify and characterize integration events in HCK cells 
containing episomal HPV16 that occur after exposure to chronic OS. The APOT data 
showed that chronic OS increases the integration rate of the HPV genome into the 
genome of these HCK cells . However, the APOT method suffers from certain 
limitations: for example not all insertions will be detected, as the events detected depend 
upon the primers chosen. Therefore, we developed a new method, based on Next 
Generation Sequencing (NGS) technology, to quantify and characterize the frequency 
and sites of HPV integration. The precise determination of integration sites using this 
NGS technique not only permits us to test our hypothesis that chronic OS promotes HPV 
integration, but also will shed light on the relationship between virus integration and the 
initial steps of transformation. Careful quantitative analysis of individual integration sites, 
immortalization and transformation events, coupled with detailed characterization of the 
sites of integration in both viral and human DNAs, will provide information on the forces 
and factors that influence viral integration. 
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Materials and Methods 
Reagents 
L-Buthionine-sulfoximine (BSO) was purchased from Sigma-Aldrich (St. Louis, 
MO). Stock solution, at a concentration of 100 mM, was prepared in phosphate-buffered 
saline (PBS) and kept at -20°C.  
Cell Culture 
Human cervical keratinocytes (HCK) containing episomal HPV16, kindly 
provided by Dr. Aloysius J. Klingelhutz (Sprague et al., 2002), were grown in E-media 
(Wu et al., 1982) with penicillin (100 U/ml) and streptomycin (100 μg/ml) (Sigma-
Aldrich, St. Louis, MO). 
Preparation of HPV-specific SureSelect Libraries 
To evaluate the integration state of HPV16 molecules and to detect the exact sites 
of integration for both human and virus DNAs, we employed the target enrichment 
approach using SureSelect DNA target baits synthesized by Agilent Technologies (Santa 
Clara, CA). Briefly, a pool of up to 16 indexed libraries prepared from the 16 DNA 
samples were sequenced simultaneously. DNA isolated from cell samples was hybridized 
to RNA SureSelect RNA baits that cover the entire HPV 8Kb genome to capture HPV-
derived sequences from the total cellular DNA, which were subjected to sequencing at 
the LLU Center for Genomics. We used CaSki DNA as a reference to evaluate the 
method since the HPV status and integration events in this cell line have been fully 
analyzed previously (Akagi et al., 2014). 
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NGS Data Analysis 
Three types of sequences were detected and analyzed: those including only HPV 
sequences, those including only human sequences, and those containing fused HPV plus 
human DNA sequences which include insertion sites. The NGS data were analyzed by 
VirusFinder freeware (Q. Wang, Jia, & Zhao, 2013). In brief, reads were first aligned 
against the human genome sequence by Bowtie2 mapping to extract non-human reads, 
which then were mapped against HPV16 DNA using the same Bowtie2 program. The 
reads that contained HPV16 sequences were analyzed for the presence of potential 
breakpoints using SVDetect and CREST detection tools.  Breakpoint sequences were 
considered indicators of HPV16 integration sites. 
Results 
Exogenous Factors Increase the Integration Rate of HPV 16 in HCK Cells Containing 
Episomal HPV16 
We employed our newly-developed NGS-based approach to identify and 
characterize integration sites in HCK cells containing episomal HPV16 following 
exposure to exogenously induced chronic OS. HCK cells were subjected to treatment 
with or without BSO, and samples were collected at day 21 as shown in Figure 7. CaSki 
cells were used as a positive control for the integrated HPV genome, since they are 
known to contain multiple copies of integrated HPV16 (Meissner, 1999). We prepared 
the SureSelect DNA libraries as described in Materials and Methods. The cellular DNA 
fragments were hybridized to RNA SureSelect RNA baits that cover the entire HPV 8Kb 
genome, then isolated and subjected to simultaneous sequencing. The NGS data were 
analyzed by VirusFinder freeware, and the results are shown in Table 2. The total number 
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of integration events identified in CaSki cells was 44, which is similar to the number of 
integration events identified previously (Akagi et al., 2014). The total number of 
integration events we detected in HCK cells treated with BSO was 19, a significant 
increase as compared to those found in the control, untreated cells in which only 2 
integration sites were detected. The results obtained by this NGS-based analysis is 
consistent with the results we found previously using the APOT method; specifically, 
both methods demonstrated that chronic OS induced by long-term BSO treatment 
increased the integration rate of the HPV16 genome.  
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Table 2. Deep sequence mapping and HPV integration across cell lines  
  
Sample ID Trimme
d Reads 
(M) 
Mappe
d to 
Human 
(M) 
Mappe
d to 
HPV 
(M) 
Unmappe
d Reads 
(M) 
Total 
Split 
Reads 
Introni
c Sites 
Intergeni
c Sites 
Tota
l 
CaSki 27.19 0.13 26.36 0.7 2,91
8 
16 28 44 
HCK 16.28 8.75 6.14 1.39 1,57
5 
1 1 2 
HCK+BS
O 
17.87 10.78 6.51 0.57 6,62
9 
10 9 19 
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Discussion 
Our NGS-based analysis demonstrated that chronic OS, as induced by exogenous 
factors, can increase the integration rate of HPV 16 into HCK cells containing episomal 
HPV16, as outlined in Figure 7. This data is consistent with the results we observed 
previously using the APOT method. 
However, the library preparation we employed includes PCR-based steps that can 
introduce false positive HPV-human amplification PCR products. For this reason, we 
plan to verify the candidate insertion sites through independent PCR analysis (Figure 8) 
in future experiments. 
HPV integration sites are distributed randomly throughout the host genome, 
without a single region predominating (Wentzensen et al., 2004). However, 38% of 192 
integrants were found in known common fragile sites (CFSs), and there was no evidence 
to suggest targeted disruption or functional alteration of critical cellular genes by the 
integrated viral sequences (Wentzensen et al., 2004). However, some studies have 
demonstrated that high-risk HPV integration has occurred within or adjacent to known 
oncogenes, most commonly within intronic sequences (Ferber et al., 2003; Thorland et al., 
2003; Wentzensen et al., 2002; Wentzensen et al., 2004). For example, the region of the 
MYC gene at chromosomal band 8q24 is a frequently observed integration site in HPV18-
positive cervical cancer (Ferber et al., 2003; Peter et al., 2006; Wentzensen et al., 2002). 
NGS-based methods now provide a very efficient method to map HPV integration sites. 
One NGS study, for example, showed that the 3'-breakpoints of integrated HPV16 DNA 
distribute preferentially within the early region E1-PAE segment in HPV 16. This 
indicates the importance of deregulated viral oncogene expression for carcinogenesis (Xu 
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et al., 2013). Interestingly, about half of the mapped HPV16 integration sites directly 
target human cellular genes (Xu et al., 2013). A genome-wide analysis of HPV 
integration in human cancer cell lines mapped HPV integrants in human cancer genomes 
and showed that they directly flank genomic structural variations, including focal 
amplifications, rearrangements, deletions, and/or translocations. These genomic 
alterations frequently disrupted the expression and structure of neighboring genes 
involved in oncogenesis, and resulted in amplification and expression of E6 and E7 
(Akagi et al., 2014). For example, the HPV integrant cluster causing homozygous 
deletion of DIAPH2 may promote chromosomal instability via misalignment of sister 
chromatids during metaphase (Cheng et al., 2011). Moreover, HPV integrants introduced 
aberrant promoters that resulted in expression of a highly expressed, truncated form of 
p63 protein containing a domain known to inhibit the pro-apoptotic protein, TAp63 
(Serber et al., 2002). The disruption of such genes by HPV integrants is likely of 
biological significance, given the established functions of affected genes. 
These studies suggest that the insertional mutagenesis of the host genome may 
play a role in cervical carcinogenesis. However, many of the previous publications using 
NGS focus on identifying genotype and determining HPV load, rather than on identifying 
sites of integration (Conway et al., 2012; Meiring et al., 2012). Our results here showed 
that we can identify HPV integration events and sites by using NGS based analysis. 
Further studies are needed to verify the candidate integration sites and assess any 
resulting genomic mutations. 
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Figure 7. Chronic OS induced by long term BSO treatment increases the integration rate 
of HPV 16 in HCK cells containing episomal HPV16.  
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Figure 8. Verification of the candidate insertion sites by independent PCR analysis.  
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CHAPTER FOUR 
OXIDATIVE STRESS MAY INFLUENCE SUSCEPTIBILITY TO CERVICAL 
CANCER: CERVICAL SPECIMENS DISPLAY VARIABILITY IN LEVELS OF 
ROS AND DNA DAMAGE 
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Abstract  
High risk human papillomaviruses (HPV) are the causative agents of cervical 
cancer. However, not all infected women develop cervical cancer. Cervical tumorigenesis 
is characterized by a multifactorial etiology, with oxidative stress (OS) likely playing a 
major role. In addition to exogenous sources, metabolic processes also contribute to OS. 
In principle, variability in levels of cervical OS has the potential to influence the 
likelihood of conversion to cervical cancer. To ask whether such variability indeed 
existed, we assessed ROS levels in normal, non-cancer cervical tissue, and demonstrated 
a greater than three-fold variability between tissues isolated from different women. 
Primary keratinocytes were also isolated and cultured, and displayed very similar levels 
of ROS as those observed in the corresponding tissue. Importantly, we demonstrated that 
the level of DNA damage in cultured cells also mirrored the level of ROS. Finally, we 
found that differences in the levels of ROS may be in part regulated by differences in the 
expression of antioxidant enzymes. Understanding the factors and mechanisms through 
which some, though not most, individuals develop cervical cancer has the potential to 
enable the development of approaches that make the conversion of HPV infection to 
cancer development even more rare. 
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Introduction 
Cervical cancer is the second most common cancer in women, and the fourth most 
common cause of cancer-related death in women worldwide (Bernard W. Stewart, 2014; 
Parkin & Bray, 2006). High risk human papilloma virus (HPV) infection is well-
established as the causative agent of cervical cancer (Ahn et al., 2003), and at least 85% 
of premalignant and 90% of malignant squamous lesions in the uterine cervix test HPV 
DNA positive (Smith et al., 2007). Infections with high-risk types of human 
papillomaviruses (HR HPV) are extremely common; approximately 20 million 
Americans are currently infected, about 15% of the total population, with another 6 
million new infections occurring each year. In more than 90% of these cases, the 
infection is cleared by the immune system within two years, especially in younger 
women and adolescents (Franco et al., 1999; Molano et al., 2003). However, a relatively 
small subset of infections persists, and of these, some progress to malignancy. In 
particular, approximately 0.3% - 0.5% of pap smear specimens are typically diagnosed 
with carcinoma in situ (Banik, Bhattacharjee, Ahamad, & Rahman, 2011), indicating that 
not all infected women develop cervical cancer, and that, in fact, the vast majority will 
not. Understanding the factors and mechanisms through which some, though not most, 
individuals develop cervical cancer has the potential to enable the development of 
approaches that make the conversion of HPV infection to cancer development even more 
rare.  
Because HPV infection alone is not sufficient to induce cervical cancer, cervical 
tumorigenesis is clearly characterized by a multifactorial etiology (H. W. Haverkos, 
2005), with oxidative stress (OS) likely playing a major role in the process  (De Marco, 
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2013; De Marco et al., 2012). A number of clinical conditions have implicated OS as a 
contributory factor, including chronic inflammation, diabetes, atherosclerosis, ischemia-
reperfusion injury and of particular interest, malignancies of different origins (Cooke, 
Evans, Dizdaroglu, & Lunec, 2003; Halliwell, 2007; Waris & Ahsan, 2006). In the case 
of cervical cancer, known risk factors in addition to HPV infection include smoking (H. 
W. Haverkos, Soon, Steckley, & Pickworth, 2003), tar-exposure (H. Haverkos, Rohrer, & 
Pickworth, 2000), co-infection with other viruses such as herpes simplex virus-2 (H. 
Haverkos et al., 2000), co-infection with other STD, lifestyle, and diet (Munoz, 
Castellsague, de Gonzalez, & Gissmann, 2006). Each of these factors can induce OS by 
one mechanism or another.  For example, smoking was shown to induce OS by 
increasing the level of free radicals (Plummer, Herrero, Franceschi, Meijer, Snijders, 
Bosch, de Sanjose, Munoz, et al., 2003; Tollefson et al., 2010). Infections and co-
infections that induce inflammation also result in increases in the levels of reactive 
oxygen species (ROS), as the innate immune defense system utilizes the induction of OS 
as a powerful weapon against pathogens (reviewed in (Y. Chen et al., 2014; Williams et 
al., 2011)). Elevated levels of reactive oxygen species (ROS) induce damage to DNA, 
lipids and proteins, damage to tumor suppressor genes, and enhanced expression of proto-
oncogenes (Halliwell, 2007; Klaunig, Kamendulis, & Hocevar, 2010). With regards to 
DNA, the ability of reactive nitrate and oxygen species to damage DNA, thereby leading 
to single and double-strand breaks, larger-scale damage and cancer, is well known 
(Cooke et al., 2003). For example, lungs of cigarette smokers contain two to three fold 
higher levels of the modified deoxynucleotide, 8-oxoguanine (Olinski et al., 1992), which 
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was shown to be induced by oxygen free radicals, resulting in inflammatory responses, 
fibrosis and tumor development (Zienolddiny, Ryberg, & Haugen, 2000). 
In addition to exogenous sources of OS such as smoking and infection, metabolic 
processes can also contribute to the level of OS in living cells. Under normal 
circumstances, homeostasis of ROS is maintained by several mechanisms, including the 
genetic and epigenetic regulation of genes coding for proteins that function in pro-and 
anti-oxidant systems (D'Autreaux & Toledano, 2007; Ray, Huang, & Tsuji, 2012). 
Individual variability in the expression and/or function of such proteins and their 
regulators has the potential to translate into variability in levels of ROS, and in fact, the 
human population has been shown to be heterogeneous with regards to ROS levels 
(Agarwal, Saleh, & Bedaiwy, 2003; Dato et al., 2013; Salganik, 2001). While the role of 
exogenous factors in influencing the risk of cervical cancer is well documented (H. 
Haverkos et al., 2000; Munoz et al., 2006), available information on the influence of 
genetic/epigenetic factors on cervical cancer risk is fragmented. Most published studies 
have focused on finding correlations between particular genetic markers or mutations 
with cancer incidence by studying tissue that is already cancerous (Zhang, Zhang, Tian, 
Yang, & Wang, 2014). Interestingly, even the question of whether cervical cancer is or is 
not hereditary is still in debate. Some consider that cervical cancer is not hereditary 
because the causative agent for cancer is HPV, which is the same for virtually all cases 
(Lynch, Casey, Shaw, & Lynch, 1998). Another group believes that because genetic 
susceptibility to HPV exposure and/or infection appears to be important in determining 
the individual risk for developing HPV-mediated cancer, this cancer could be considered 
to have a hereditary component (Magnusson & Gyllensten, 2000).  
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We suggest that a high level of ROS in cervical tissue, which may result from a 
combination of external influences as well as internal, genetic/epigenetic factors, has the 
potential to contribute to the likelihood that a particular woman will develop cervical 
cancer. To assess this possibility, we characterized normal, non-cancer cervical tissue for 
levels of ROS, and demonstrated a greater than three-fold variability in the levels of ROS 
between tissues isolated from different women. Primary keratinocytes were also isolated 
and cultured from these specimens, and displayed levels of ROS that were very similar to 
those observed in the corresponding tissue. Importantly, we demonstrated that the level of 
DNA damage also mirrored the level of ROS in cultured cells. Finally, we found that 
differences in the level of ROS may be in part regulated by differences in the expression 
of antioxidant enzymes. 
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Material and Methods 
Preparation of Cervical Specimens 
Normal cervical specimens were collected from patients with uterovaginal pelvic 
organ prolapse following vaginal hysterectomy at the Loma Linda University Surgical 
Hospital. Samples were anonymized to prevent linkage to identifiable individual data. 
Waste tissues not needed for clinical analysis were collected and placed into 0.9% normal 
saline solution and transported to the laboratory. Each specimen was then dissected in 
cold PBS under sterile cell culture conditions. The transformation zone (TZ) and 
ectocervical (EC) regions were separated and divided into several parts for further use. 
ROS Analysis - Cervical Tissue 
Specimens isolated from the TZ and EC were weighed and transferred to glass 
vials containing PBS for homogenization. The volume of PBS used for each sample was 
calculated to yield 200 mg of tissue in 1 ml of PBS. Homogenates were centrifuged at 
10,000 rpm for 5 min at 4oC, after which the supernatant was transferred to a new 
eppendorf tube, then snap-frozen in liquid nitrogen and stored at -80oC until use. During 
homogenization, the free radicals will be released to the PBS according to manufacture 
instruction. 
ROS levels in these homogenate supernatants were measured using the OxiSelect 
In Vitro ROS/RNS assay kit (Cell BioLabs, San Diego, CA) according to the 
manufacturer’s protocol. Hydrogen peroxide (H2O2), hydroxyl (OH-) and peroxyl (ROO-) 
radicals were detected using dichlorodihydrofluorescin (DCFDA). Protein concentrations 
were measured with the Coomassie Plus Assay Reagent (Thermo Fisher Scientific, 
Rockford, IL) and used for normalization. 
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Isolation and Culturing of Normal Primary Cervical Keratinocytes 
Primary keratinocytes from TZ and EC regions were isolated using the protocol 
“Isolation, Primary Culture, and Cryopreservation of Human Keratinocytes” from 
Thermo Fisher Scientific (Life Technologies). Cells were maintained in keratinocyte 
growth media, E-media (Piboonniyom et al., 2003), with the feeder layer provided by 
mouse NIH 3T3 fibroblasts treated with 4 µg/ml of Mitomycin C (Sigma-Aldrich, St. 
Louis, MO) for 4 h. To prevent keratinocyte differentiation, 10 µM of the ROCK 
pathway inhibitor, Y-27632 (Tocris, Bristol, UK), was included in the culture medium. 
ROS Analysis – Cultured Keratinocytes 
Intracellular generation of H2O2, OH
- and ROO- radicals, as well as of superoxide 
(O2
−), was estimated using either the 5-(and-6)-Carboxy-2',7'-Dichlorodihydrofluorescein 
diacetate (DCFDA) or Dihydroethidium (DHE) membrane permeable probes (Thermo 
Fisher Scientific, Life Biosciences), respectively. Reagents were diluted into culture 
media, and then added to cells to a final concentration of 10 µM. After treatment, the 
cells were collected in 1X PBS and analyzed using the Becton-Dickinson FACSCalibur 
flow cytometer (Becton-Dickinson, San Francisco, CA). DCFDA was detected in the FL-
1 channel, while DHE was detected in the FL-2 channel. Data was collected in log scale 
and analyzed using Flow-Jo software. 
Immunoblot Assays 
106 cells were lysed in 100 µl of Laemmli lysis buffer, and lysates were sonicated 
and separated by SDS-PAGE. After the transfer of protein onto PVDF membranes 
(Thermo Fisher Scientific, Life Technologies) and blocking of the membrane in Odyssey 
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Blocking Buffer (Li-COR, Lincoln, NE), primary antibodies were applied overnight. 
Monoclonal α-β-actin antibodies were obtained from Sigma-Aldrich (St. Louis, MO), 
monoclonal α-superoxide dismutase1 (SOD1), α-glutathione reductase (GR)  and α-
glutathione peroxidase (Gpx ½) antibodies from Santa Cruz Biotechnology (Santa Cruz, 
CA), and monoclonal α-superoxide dismutase 2 (SOD2) antibodies from BD Biosciences 
(San Jose, CA). Secondary goat anti-mouse IRDye 800 CW (Li-COR, Lincoln, NE) was 
applied onto the membrane for 1 h, and the detection of signal was performed using 
Odyssey Imaging System (Li-COR, Lincoln, NE). 
DNA Damage - 8-Oxyguanine Analysis 
Avidin-FITC (Thermo Fisher Scentific, Life Technologies) was used to measure 
8-oxoguanine levels in cells (Achanta & Huang, 2004). Cells were fixed in 1% 
paraformaldehyde and permeabilized in methanol. 10 µM of Avidin-FITC was applied to 
cells for 1 h, and after two washes, binding of the Avidin-FITC-conjugate to 8-
oxoguanine in cells was monitored using flow cytometery (excitation 495 nm, emission 
515 nm) on a BD FACS Calibur (BD, Franklin Lakes, NJ), then analyzed using Flow-Jo 
software. A total of 10,000 events were measured per sample. 
Statistics 
All measurements for ROS levels were performed in triplicate, and error bars on 
graphs represent standard deviations. The F-test was used to determine whether the 
variances between two variables was significant. 
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Results 
Collection and Preparation of Cervical TZ and EC Specimens 
Cervical tissue includes the endocervix, the transformation zone, and the 
ectocervix. The endocervical mucosa is lined with a single layer of columnar mucous 
cells within the endocervical canal, while the ectocervix is covered with nonkeratinized 
stratified squamous epithelium directed towards the vaginal portion of the cervix (Gray, 
Williams, & Bannister, 1995). The junction between these two types of epithelia is called 
the squamocolumnar junction (SCJ) (Beckmann & American College of Obstetricians 
and Gynecologists., 2014). In prepubertal females, the functional SCJ is present within 
the endocervical canal. Upon entering puberty, hormonal influences cause the columnar 
epithelium to extend outwards over the ectocervix as the cervix everts, and also cause the 
SCJ to move outwards onto the vaginal portion of the cervix (Beckmann & American 
College of Obstetricians and Gynecologists., 2014). The zone of unstable epithelium 
between original SCJ and the new SCJ, which is internal to the original SCJ, is called the 
transformation zone (TZ) (Beckmann & American College of Obstetricians and 
Gynecologists., 2014). The TZ is a highly active metaplastic tissue in which the single 
layer columnar epithelium is transformed into the multilayered squamous epithelium of 
the ectocervix (EC).  The cells of this zone, which are organized as single layer 
epithelium, are potential targets for HPV infection (Schiffman, Castle, Jeronimo, 
Rodriguez, & Wacholder, 2007).  If these TZ cells are infected with HPVs, they can 
become the primary sites for cervical intraepithelial neoplasia development after 
replacement by non-keratinized stratified squamous epithelium (Schiffman et al., 2007). 
Because these TZ cells are the likely targets for HPV, they were chosen for further 
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investigation. The corresponding EC cells were also analyzed, as they also play a role in 
the virus life cycle.  
Normal cervical tissue, isolated from patients undergoing vaginal hysterectomy, 
was dissected in cold PBS.  The TZ and EC portions were separated, and specimens were 
prepared for measuring tissue ROS levels and for isolating primary keratinocytes for 
subsequent in vitro culturing. Specimens from 19 patients were collected and subjected to 
analysis of ROS levels, while the comparison of ROS levels between TZ and EC tissues 
was performed on specimens isolated from 5 patients. Specimens isolated from 5 patients 
were employed for isolation and culturing of primary keratinocytes from the TZ and EC 
regions. The histology of the TZ and EC regions after dissection of specimen #20 are 
shown in Figure 9.  The TZ region is characterized by single layer epithelium (Figure 
9A), while the EC displays a morphology of multilayered squamous epithelium with 
basal/parabasal, intermediate and superficial layers (Figure 9B). 
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Figure 9. Representative specimen #20 showing TZ (A) and EC (B) tissues isolated from 
the cervix. After dissection, the tissues were fixed in 4% paraformaldehyde, embedded in 
paraffin, sectioned and stained with hematoxylin-eosin.   
Figure	1	
A	 B	
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ROS Levels in Cervical TZ tissues Differ Within a Three-fold Range Between Patients 
The observation that OS is a promoting factor for numerous pathologies, 
including several types of cancer, suggested that an excess of free radicals could also 
contribute to HPV-induced cervical tumorigenesis. In particular, it seemed possible that 
differential background levels of ROS in cervical cells, caused by some combination of 
differences in genetic/epigenetic backgrounds together with variable exposure to 
exogenous factors, might contribute to the likelihood that a particular HPV-infected 
woman might or might not progress to cancer. To assess how the level of ROS in cervical 
tissues from different women might vary, TZ specimens isolated from nineteen patients 
after vaginal hysterectomy were subjected to ROS analysis, and the level of H2O2, OH
- 
and ROO- radicals was detected using DCFDA. The data obtained (Figure 10A) 
demonstrate significant variability between patients in the level of ROS found in their 
TZ. For example, the lowest level of ROS was noted in sample #15 (717 FLU/µg of 
protein), while the highest was noted in sample #16 (2334 FLU/µg protein). This 
represents a difference of more than 3-fold. ROS levels for the other samples are 
distributed between these values (Figure 10A).  
As noted above, TZ cells are the primary targets for HPV infection. However, 
after replacement with non-keratinized stratified squamous epithelium, the HPV life 
cycle takes place in the multilayered squamous epithelium of the EC. We measured and 
compared ROS levels between single- and multilayered epithelium from the cervix, 
tissues that differ both functionally and structurally. Figure 10B shows the ROS levels 
observed in homogenates prepared from the TZ and EC regions of 5 specimens. Within 
each pair (TZ and EC), the ROS level in the TZ was higher than or approximately equal 
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to that seen in the EC. For example, in sample #16, the difference between the TZ and EC 
was more than two-fold, while in samples #17 and #20, there was no significant 
difference between the two. The ROS levels observed in the TZ and EC regions are likely 
to reflect contributions from genetic/epigenetic regulation of ROS levels, together with 
influences from exogenously-derived factors such as exposure to drugs, environmental 
factors and life style. 
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Figure 10. ROS levels in cervical TZ tissues. (A) ROS levels in cervical TZ tissues differ 
within a range of three-fold between patients. Homogenates were prepared from TZ tissues 
immediately after surgery, and ROS levels were assessed using the OxiSelect In Vitro 
ROS/RNS assay kit (Cell BioLabs) according to the manufacturer’s protocol. Protein 
concentrations were measured with the Coomassie Plus Assay Reagent (Thermo Scientific) 
and used for normalization. ROS levels are represented as fluorescent light units (FLU)/µg 
protein. (B) Tissue homogenates prepared from the TZ have greater or equal levels of ROS 
than do homogenates prepared from the EC. The level of ROS in 5 TZ and EC tissue 
homogenates was measured as described in A). All measurements were performed in 
triplicate, and error bars represent the standard deviation.  
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Culture of Primary Keratinocytes 
Dissection of the primary tissue enables us to obtain approximately 200 mg of TZ 
or EC tissues, which consists of a keratinocyte layer, along with fat and connective 
tissues. This amount of material is sufficient for only a limited number of studies. 
Therefore, in order to increase the amount of material available for investigations focused 
on areas such as the modeling of HPV infection, HPV integration and cellular 
transformation, we applied known procedures to isolate and culture primary keratinocytes 
from the EC and TZ cervical tissues. One property that frequently restricts keratinocyte 
production is the well-known fact that primary keratinocytes in culture undergo terminal 
differentiation after several divisions. We were able to overcome this restriction and 
create a culture that can divide indefinitely by blocking the ROCK pathway using the Y-
27632 inhibitor of serine/threonine kinases ROCK-I and ROCK-II (McMullan et al., 
2003). Application of ROCK inhibitors to keratinocytes has been shown to prevent 
terminal differentiation and induce cell division (McMullan et al., 2003). Using Y-27632, 
we were able to maintain the keratinocyte culture for 5 months without noticeable 
changes in the growth rate or morphology. The morphology of our cervical keratinocytes 
grown in culture is shown in Figure 11. The primary keratinocytes isolated from EC 
tissue and grown in culture in the presence of Y-27632 are represented by only one type 
of small cells (Figure 11A), while keratinocytes isolated from the TZ consist of at least 
two types of cells that may represent keratinocytes at different differentiation states. One 
type appears similar to the keratinocytes isolated from the EC, while the other type is 
larger (Figure 11B). 
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Figure 11. Morphology of cultured keratinocytes isolated from EC and TZ. Arrows 
indicate clusters of keratinocytes. Feeder cells can be seen around the clusters.  
  
Figure	3		
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Variability in ROS Levels in Cultured Primary Keratinocytes Isolated from the TZ is 
Higher than in Keratinocytes Isolated from the EC 
To assess how closely our cultured primary keratinocytes reflected the levels of 
ROS observed in their corresponding tissues of origin, we measured the levels of ROS in 
primary keratinocytes isolated from the TZ and EC regions of 5 patients. Estimation of 
ROS levels in cultured cells was performed following staining of cells with DCFDA 
(which detects H2O2, OH
- and ROO-) and with DHE (which detects O2
-) (Peshavariya et 
al., 2007) followed by flow cytometry. Surprisingly, the level of superoxides as detected 
by DHE in cultured keratinocytes was approximately the same for both EC and TZ 
keratinocytes, and did not vary significantly between patients (Figure 12A, grey bars). In 
contrast, the level of ROS as detected by DCFDA was highly variable, both between TZ 
and EC keratinocytes and between patients (Figure 12A, black bars). One representative 
flow profile of DCFDA-detected ROS from EC and TZ keratinocytes (isolated from 
patient #16) is presented in Figure 12B. The lowest levels of DCFDA-detected ROS were 
found in the EC and TZ keratinocytes isolated from patient #20, while the highest values 
were detected in patient #16, with corresponding differences between ROS in TZ and EC 
keratinocytes of approximately 1.3 and 2, respectively (Figure 12A). The difference in 
the levels of DCFDA-detected ROS between EC keratinocytes isolated from different 
women was approximately 3-fold, while the difference between TZ keratinocytes was 
nearly 5-fold (Figure 12A).  Interestingly, the level of ROS in keratinocytes isolated from 
the TZ was higher than in keratinocytes isolated from the EC in all 5 specimens (Figure 
12A). Because the keratinocytes were isolated, cultured and grown in vitro conditions, it 
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is likely that the observed level of ROS is largely driven by biological factors such as the 
cell’s genetic and epigenetic background. 
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Figure 12. Cultured primary keratinocytes isolated from the TZ display higher levels of 
ROS than do keratinocytes isolated from the EC. (A) The level of ROS detected by DCFDA 
varies between patients, while the level of superoxides detected by DHE does not change. 
ROS levels were detected by flow cytometry after staining with DCFDA and DHE. 
Measurements were done in triplicate, and the mean fluorescent intensity (MFI) was 
estimated using FlowJo software. (B) A representative flow diagram for TZ and EC 
keratinocytes isolated from specimen #16.  
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ROS Levels in Tissue Homogenates Correspond to Those Observed in Cultured 
Keratinocytes 
To assess how well the cultured keratinocytes reflect the primary tissue from 
which they were derived, we compared the levels of ROS detected in tissues with those 
observed in cultured keratinocytes isolated from those same tissues. The values obtained 
are shown in the same graph (Figure 13). These results revealed a good correlation 
between ROS levels in tissue and the corresponding cultured keratinocytes.  To 
determine whether the variances in ROS levels between tissues and the corresponding 
cultured keratinocytes were significantly different, we employed the F-test. The F-value 
was equal to 1.4, a value that is lower than F-critical (3.79), thereby demonstrating that 
the two variables do not differ significantly and that the difference between values could 
be explained by random events. 
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Figure 13. ROS levels in cervical tissues mirror the ROS levels observed in the 
corresponding cultured keratinocytes. ROS levels from TZ tissues (presented in Figure 
10A) and in the corresponding cultured keratinocytes (presented in Figure 12A) are plotted 
on the same graph. ROS levels (in MFI) for cultured keratinocytes are shown as stacked 
areas, while the ROS levels in tissues (FLU/µg protein) are presented as bars. The F-test 
was used to determine whether the variances in ROS levels for tissues and in ROS levels 
for cultured keratinocytes were significantly different.  
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Low Levels of Gpx1/2, an Antioxidant Enzyme, Correlate with Higher Levels of ROS 
in TZ Keratinocytes. 
ROS levels in cells reflect the functions of both pro-and anti-oxidant enzyme 
systems (D'Autreaux & Toledano, 2007; Ray et al., 2012). Previously, we demonstrated 
that the increase in ROS levels following HPV16 E6* expression is due to a reduction in 
the expression of SOD2 and GPX1/2 (Williams et al., 2014b). For this reason, we 
considered the possibility that our currently observed difference in ROS levels between 
TZ- and EC-derived cells could also be a result of differential expression of anti-oxidant 
enzymes. To test this idea, we compared the expression level of four anti-oxidant 
enzymes, SOD1, SOD2, Gpx ½ and Glutahione reductase (GR), in keratinocytes derived 
from patients #14 and #16. These two sets were chosen because they displayed 
significant differences in ROS levels between their TZ and EC keratinocytes (Figure 
12A). Immunoblot analysis clearly demonstrated that Gpx1/2 expression was lower in TZ 
than in EC cells, while no significant difference in the expression of the other enzymes 
was observed (Figure 14). This observation is consistent with the idea that the differences 
in ROS observed between TZ and EC keratinocytes could be a result of differences in the 
expression of certain antioxidant enzymes. 
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Figure 14. Decreased levels of GPX1/2 expression were observed in TZ keratinocytes as 
compared to EC keratinocytes. Immunoblot analysis was carried out for cultured EC and 
TZ cells isolated from specimens #14 and #16, and normalized to β-actin expression. GPX 
½ - glutathione peroxidase, GR – glutathione reductase, SOD1 and SOD2 – superoxide 
dismutase 1 and 2.   
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High Levels of 8-Oxoguanine, a Marker of DNA Damage, Correlate with Higher 
Levels of ROS 
One major outcome of higher levels of cellular ROS is an induction of chronic 
OS. OS is well known for its ability to damage multiple biomolecules, including DNA, 
and the oxidation-induced incorporation of 8-oxoguanine into DNA lesions can lead to 
mismatch mutations during DNA synthesis (Cooke et al., 2003; Olinski et al., 1992). The 
data shown in Figure 12 demonstrates that ROS levels in keratinocytes differ both 
between TZ- and EC-derived cells, and between specimens derived from different 
patients. The well-established linkage between OS and DNA damage therefore suggested 
that cells with higher levels of ROS would also display higher level of 8-oxoguanine. To 
test this idea, we measured the level of 8-oxoguanine in cultured keratinocytes that 
displayed variable levels of ROS. 8-oxoguanine levels were estimated by flow cytometry 
following Avidin-FITC staining, as avidin is able to bind to lesions containing 8-
oxoguanine (Achanta & Huang, 2004). Figure 15 presents the measured levels of 8-
oxoguanine together with DCFDA-detected levels of ROS. The highest level of ROS was 
detected in TZ keratinocytes isolated from specimen #16; these cells are also the ones 
displaying the highest level of 8-oxoguanine. We also note that cells isolated from the 
same patient, but derived from the EC, displayed lower levels of both ROS and 8-
oxoguanine than did the corresponding TZ cells (Figure 15). The other specimens also 
displayed good correspondence between their levels of ROS and 8-oxoguanine (Figure 
15). Furthermore, the variability observed between these two variables is not significant 
as estimated by the F-test.  These data, therefore, are consistent with the idea that higher 
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levels of cellular oxidative stress, as determined by increased levels of ROS, cause a 
downstream increase in the level of DNA damage. 
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Figure 15. ROS and DNA damage levels in cervical keratinocytes closely mirror each 
other. DNA damage was assessed by detection of 8-oxoguanine using Avidin-FITC. Cells 
were fixed in 4% paraformaldehyde, washed and stained with 50 µM of Avidin-FITC for 
1 h. The level of bound Avidin-FITC, presented as mean fluorescent intensity (MFI 
(Avidin-FITC)) was detected by flow cytometry and analyzed using FlowJo software. ROS 
levels were measured as described for Figure 12A. The MFI values for DNA damage 
(Avidin-FITC staining) and for ROS (DCFDA staining) were plotted on the same graph. 
To determine whether the variances in ROS levels and in 8-oxoguanine levels were 
significantly different, the F-test was used.  
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Discussion 
In this report, we demonstrate for the first time a significant variability between 
women with regards to the background levels in ROS levels found in their cervical TZ 
tissue (Figure 10A). In particular, the difference between the lowest and highest levels of 
H2O2, OH
- and ROO- species, as detected with DCFDA, was approximately 3-fold. It is 
generally assumed that the TZ epithelium is the site of neoplastic changes, and the most 
common area for the origination of cervical cancer (Herfs et al., 2012; Schiffman et al., 
2007).  The formation of cervical lesions may be facilitated by HPV infection of TZ cells, 
which can subsequently go on to form the basal layer of the stratified epithelium where 
HPV life cycle occurs.   
The importance of our observation may lie in the possible clinical consequences 
of higher levels of ROS in the cervices of some woman, and in particular, how these 
higher levels of ROS may affect the integration of HPV.  In 88% of specimens obtained 
from cervical cancers, HPV DNA was found integrated into the host genomes (Klaes et 
al., 1999). Therefore, an integration of HPV genome into that of the host is considered to 
function as a critical step in the development of many or most cases of cervical cancer. In 
many cases, the mechanism through which HPV integration leads to cancer development 
is thought to be a loss of functional E2 (a negative regulator of E6 and E7 expression) 
due to linearization, followed by increased expression of the E6 and E7 oncogenes. The 
resulting over-expression of E6 and E7 increases cellular proliferation at the same time 
that it decreases responsiveness to apoptotic signals.  
Integration proceeds by way of non-homologous recombination, and therefore 
requires linearization of the episome and breakage of the host chromosome. 
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Epidemiological and molecular data both point toward OS as an important contributor to 
viral integration. For example, epidemiological data link conditions known to cause OS 
and DNA damage, such as smoking and co-infection with the STD-associated pathogens 
Chlamydia trachomatis and Neisseria gonorrhoeae, with increased incidence of HPV-
mediated cancers (reviewed in (Y. Chen et al., 2014; Williams et al., 2011)). Recently, 
we demonstrated that depletion of the antioxidant glutathione induced OS in cells and led 
to an increase in the frequency of HPV integration in human cervical keratinocytes that 
contained episomal HPV (Chen Wongworawat, Filippova, Williams, Filippov, & 
Duerksen-Hughes, 2016). Consistent with these proposed connections between OS, DNA 
damage, HPV integration and cancer, integration associated with oxidative stress has 
been demonstrated for another DNA virus, Hepatitis B (Cougot et al., 2005; Hu et al., 
2010; Petersen et al., 1997). In the examples discussed above, the etiological factors that 
promote HPV-induced carcinogenesis by increasing the probability of HPV integration 
likely include environmental agents that can directly or indirectly increase cellular OS 
and the resulting DNA damage. Virus-derived factors, such as co-infection with other 
viruses, viral load and persistence of HPV infection can also promote HPV integration 
(Munoz et al., 2006). These virus-associated factors may also be connected to increased 
OS; recently, we demonstrated that expression of the E6 splice variant, E6*, but not the 
full-length version of E6, induced increases in ROS, DNA damage (Williams et al., 
2014b) and the frequency of foreign DNA integration (Chen Wongworawat et al., 2016).   
In addition to the exogenously-derived risk factors discussed above, Munoz et al 
(Munoz et al., 2006) have suggested that host-related factors, such as endogenous 
hormone levels, genetic background and factors related to the immune response, could 
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also contribute to cancer promotion. Logic for this suggestion comes from the fact that 
under normal circumstances, ROS levels are maintained in a condition of homeostasis by 
balanced functioning of pro- and anti-oxidant systems (D'Autreaux & Toledano, 2007; 
Ray et al., 2012) that are regulated by individual genetic determinants. In addition to such 
genetic determinants, life-style and physiological factors can also influence gene 
expression levels through changes to epigenetic regulation (Jaenisch & Bird, 2003). Both 
genetic and epigenetic factors are examples of biological factors that can contribute to the 
variability in levels of ROS observed in different individuals.  
The evidence presented in this report indicates an important role for individual 
genetic and epigenetic variation in determining the overall level of cellular ROS and 
importantly, the resulting level of DNA damage. For the first time, we have demonstrated 
that individual women display significantly different levels of DNA damage in their 
cervical cells (Figure 15). Furthermore, the levels of ROS correlate with those of DNA 
damage. The higher levels of ROS seen in some women may reflect variability in 
mutation rates, and, if these women were to be harboring episomal HPV DNA, could 
result in an increased probability of integration. In addition, high levels of ROS in TZ 
cells infected with HPV have the potential to increase expression of the E6/E7 oncogenes 
(Wei et al., 2009), leading to higher level of DNA damage (Wei et al., 2014), and inhibit 
pro- and repress anti-tumor pathways (Valko, Rhodes, Moncol, Izakovic, & Mazur, 
2006a). It is well known that OS itself is a tumor-promoting factor; in cooperation with 
HPV, it becomes a more potent carcinogen.  
The results reported here also address the question of the relative roles played by 
environmental agents and other external factors vs internal factors such as genetic 
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variation and epigenetic programming. While acute OS induced by exogenously-derived 
factors can, in principle, be eliminated by removing the insult, the effect on cellular OS 
exerted by biological factors represents a more chronic and constant influence. The 
variability of ROS levels in cervical tissues observed in different women (Figure 10A) 
could, in principle, be mediated both by exogenous factors and by genetic/epigenetic 
factors that control the level of ROS, as the genetic and epigenetic capacity of cells to 
deal with oxidative stress will affect the ability of those cells to deal with both 
endogenous and exogenous insults. In contrast, the cultured keratinocytes from different 
individuals represent a model system in which variability in the influence of exogenous 
factors is removed because the cells are maintained in the same in vitro conditions for an 
extended period. The comparison of ROS levels between cervical tissues and cultured 
keratinocytes revealed a strong similarity, indicating that ROS levels in tissues are likely 
determined primarily by biological factors (Figures 10 and 12) since the pattern of ROS 
level in tissue samples was similar to the pattern seen in the corresponding primary 
keratinocytes (Figure 13). For example, in tissue homogenates and in cultured cells 
isolated from sample #16, the levels of ROS detected by two independent methods 
showed a similar pattern in which the level was lower in EC keratinocytes and higher in 
TZ keratinocytes. The slightly higher level of ROS noted in homogenates of #18 EC, #20 
EC and #20 TZ as compared to the corresponding cells may be due either to the influence 
of exogenous factors or by random fluctuations (Figure 13). An F-test performed on the 
two variables favors the explanation of random fluctuations. Overall, these results 
suggest that the level of ROS in cervical tissues primarily determined by biological 
factors. This finding is important for future studies, as it provides direction toward 
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inquiries designed to understand why the disease is more prevalent in certain populations 
than in others. In addition, the close correlation between tissues and their corresponding 
cells indicates that further experiments focused on the role of ROS in HPV-mediated 
cervical carcinogenesis can be carried out using unrestricted cellular material derived 
from real patients.  
Interestingly, a comparison of ROS levels between single- (TZ) and multilayered 
(EC) epithelium from cervix has not been previously reported. We found that ROS levels 
in TZ tissue were higher than or equal to the ROS levels found in the corresponding EC 
tissue (Figure 10B). A similar observation was made with the cultured keratinocytes 
(Figure 12B). This difference may suggest a reason that TZ tissue is the primary target 
for HPV infection/cervical cancer. 
The difference between EC and TZ cells with regards to their ROS levels as 
detected by DCFDA is consistent with, and may be caused by, a differential level of 
expression of the antioxidant enzyme, Gpx ½ (Figure 14). While the level of superoxide-
converting enzymes such as SOD1 and SOD2 (McCord & Fridovich, 1988) was 
unchanged, the level of Gpx ½, which converts H2O2 molecules to water in the presence 
of glutathione (McCord & Fridovich, 1988), was lower in TZ than in EC cells (Figure 
14), coincident with the higher level of ROS in these cells. Interestingly, the level of 
superoxide radicals as detected by DHE (Figure 12A) was similar between EC and TZ 
cells; this is consistent with the similar levels of SOD1 and SOD2 expression observed in 
these cells (Figure 14). These data provide a possible mechanistic explanation of the 
lower level of species such as H2O2, OH
- and ROO- that were observed in EC as 
compared to TZ cells (Figure 12A).   
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Overall, our findings point toward significant variability in ROS levels among 
women, and shed light on the potential contribution of increased levels of ROS, and the 
genetic/epigenetic contexts that support these increased levels, to HPV-mediated 
carcinogenesis. Future research will focus on exploring the possibility that high levels of 
ROS may predispose certain infected women – and populations - to HPV-mediated 
carcinogenesis. Our overall goal is to develop an understanding of the underlying 
mechanisms so as to develop novel and effective ways to intercept cancer development in 
HPV-infected individuals. 
 
Conclusions 
We characterized normal, non-cancer cervical tissue for their levels of ROS, and 
demonstrated a greater than three-fold variability in the levels of ROS between tissues 
isolated from different women. Primary keratinocytes were also isolated and cultured 
from the specimens, and displayed levels of ROS that were very similar to those observed 
in the corresponding tissue. Importantly, we demonstrated that the level of DNA damage 
also mirrored the level of ROS in both cultured cells. Finally, we found that differences 
in the level of ROS may be in part regulated by differences in the expression of 
antioxidant enzymes. 
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CHAPTER FIVE 
DISCUSSION 
Viruses have been demonstrated to be the causative agents of approximately 
10%–15% of all cancers worldwide. When acting as carcinogenic agents, viruses utilize a 
variety of mechanisms to transform human cells. Their genome encodes proteins that 
reprogram the normal functioning of cells so as to favor virus production, and the most 
common outcome for this virus-induced reprogramming is the induction of genomic 
instability, as seen by the accumulation of point mutations, aberrations and DNA damage. 
However, the mechanisms causing this genomic instability differ between viruses. 
Genomic instability caused by viruses serves as a major step on the pathway leading to 
carcinogenesis and can be induced by viral infection and inflammation, by viral gene 
expression and by exogenously derived factors. All of these mechanisms can lead to 
increased oxidative stress, which is then able to damage host DNA. For some viruses, 
such as HBV, HPV and MCV, the pivotal step of the onset of tumorigenesis appears to be 
integration of the viral genome, which elevates viral oncogene expression and promotes 
cancer progression. Typically, cancer develops years to decades following the initial 
infection. This provides us with a unique opportunity for cancer interception, especially in 
cases where the tumorigenesis process requires virus integration. 
In the case of HPV, potential cofactors that promote cervical carcinogenesis can 
be thought of as being classified into three groups: (1) environmental or exogenous 
cofactors, including hormonal contraceptives, tobacco smoking, parity, and co-infection 
with other sexually transmitted agents; (2) viral cofactors, such as infection by specific 
types, co-infection with other HPV types, HPV variants, viral load, and viral integration; 
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and (3) host cofactors, including endogenous hormones, genetic factors, and other factors 
related to the immune response (Munoz et al., 2006). Our results demonstrate that chronic 
OS, induced either by viral factors such as E6* or by exogenous factors, can induce DNA 
damage and increase the integration rate of both plasmid DNA and the HR HPV genome, 
and in this way contribute to cervical carcinogenesis. We also characterized normal, non-
cancer cervical tissue and the corresponding primary keratinocytes for levels of ROS, and 
found that the values observed between primary tissue and isolated keratinocytes were 
very similar to each other, while displaying  significant variability between patients. 
These findings shed light on the potential contribution of increased levels of ROS, and 
the genetic/epigenetic contexts that support these increased levels, to HPV-mediated 
carcinogenesis. In summary, we connected these three groups of potential cofactors that 
promote cervical carcinogenesis to a chain of events leading from the induction of OS to 
DNA damage and then to HPV integration, and finally, to the development of cervical 
cancer.  
Our increasing understanding of the contributions of viral, exogenous and host 
cofactors to the etiology of cervical carcinogenesis, as well as of the networking of 
pathways involved in the transitions from OS induction, to DNA damage, to integration 
and finally to cervical cancer will continue to suggest prophylactic and therapeutic 
strategies to reduce the risk of HPV-mediated cervical cancer. However, the detailed 
mechanisms of OS induced DNA damage in HPV integration and carcinogenesis are still 
not fully understood and require further study  (Figure 16). 
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Figure 16. Potential cofactors that can promote cervical carcinogenesis. These cofactors 
can be classified into three groups: (1) environmental or exogenous cofactors; (2) viral 
cofactors; and (3) host cofactors (Munoz et al., 2006). Our results increase the 
understanding of the contributions of viral, exogenous and host cofactors to the etiology of 
cervical carcinogenesis, as well as of the networking of pathways involved in the transitions 
from OS induction, to DNA damage, to integration and finally to cervical cancer.  
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